: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

Leukemia

Free Subscription

Articles published in Blood
Retrieve available abstracts of 723 articles:
HTML format

Single Articles

May 2024

WOYACH JA, Jones D, Jurczak W, Robak T Prof, et al
Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib.
Blood. 2024 May 16:blood.2023023659. doi: 10.1182/blood.2023023659.
PubMed Abstract available

MRD and EFS in pediatric T-lymphoblastic lymphoma.
Blood. 2024;143:2111.
PubMed

Silva A, Almeida ARM, Cachucho A, et al. Overexpression of wild-type IL-7Ralpha promotes T-cell acute lymphoblastic leukemia/lymphoma. Blood. 2021;138(12):1040-1052.
Blood. 2024;143:2108-2110.
PubMed

RIBERA JM
MRD: also for T-lymphoblastic lymphoma.
Blood. 2024;143:2017-2019.
PubMed

TAMENI A, Toffalori C, Vago L
Tricking the Trickster: Precision Medicine Approaches to Counteract Leukemia Immune Escape after Transplant.
Blood. 2024 May 10:blood.2023019962. doi: 10.1182/blood.2023019962.
PubMed Abstract available

LE RQ, Przepiorka D, Chen H, Shen YL, et al
Complete Remission with Partial Hematological Recovery as a Palliative Endpoint for Treatment of Acute Myeloid Leukemia.
Blood. 2024 May 10:blood.2023023313. doi: 10.1182/blood.2023023313.
PubMed Abstract available

RECHER C
Transplant in AML: just follow the NPM1 guide!
Blood. 2024;143:1881-1882.
PubMed

SUNG PJ
PIKing the right target in AML.
Blood. 2024;143:1884-1885.
PubMed

OTHMAN J, Potter N, Ivey A, Jovanovic J, et al
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.
Blood. 2024;143:1931-1936.
PubMed Abstract available

GOKBUGET N, Boissel N, Chiaretti S, Dombret H, et al
Management of ALL in adults: 2024 ELN recommendations from a European expert panel.
Blood. 2024;143:1903-1930.
PubMed Abstract available

GOKBUGET N, Boissel N, Chiaretti S, Dombret H, et al
Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel.
Blood. 2024;143:1891-1902.
PubMed Abstract available

April 2024

ROESSNER PM, Seufert I, Chapaprieta V, Jayabalan R, et al
T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia.
Blood. 2024 Apr 29:blood.2023021990. doi: 10.1182/blood.2023021990.
PubMed Abstract available

KRAKOW EF, Brault M, Summers C, Cunningham TM, et al
HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.
Blood. 2024 Apr 29:blood.2024024105. doi: 10.1182/blood.2024024105.
PubMed Abstract available

WIENECKE CP, Heida B, Venturini L, Gabdoulline R, et al
Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation.
Blood. 2024 Apr 26:blood.2023022697. doi: 10.1182/blood.2023022697.
PubMed Abstract available

SUBKLEWE M
T cells take aim in AML: targeting IDH2.
Blood. 2024;143:1681-1682.
PubMed

ABDELBAKY SB, Giacopelli B, Rabe KG, Yamaguchi K, et al
Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature.
Blood. 2024;143:1752-1757.
PubMed Abstract available

TRAN TH, Tasian SK
How I Treat Philadelphia Chromosome-like Acute Lymphoblastic Leukemia in Children, Adolescents, and Young Adults.
Blood. 2024 Apr 24:blood.2023023153. doi: 10.1182/blood.2023023153.
PubMed Abstract available

LAMBLE AJ, Rau RE
IFN-gamma and CD38 in AML: a T-cell engagement made in heaven?
Blood. 2024;143:1556-1557.
PubMed

CUNEO A, Ghia P
Ibrutinib in CLL: benefit for all?
Blood. 2024;143:1558-1559.
PubMed

BUFFET R
How lipid coating soothes the gut in AML therapy.
Blood. 2024;143:1559-1561.
PubMed

RENGA G, Nunzi E, Stincardini C, Pariano M, et al
CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization resistance, and immune homeostasis.
Blood. 2024;143:1628-1645.
PubMed Abstract available

WOYACH JA, Perez Burbano G, Ruppert AS, Miller C, et al
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.
Blood. 2024;143:1616-1627.
PubMed Abstract available

LANGERBEINS P, Giza A, Robrecht S, Cramer P, et al
Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
Blood. 2024 Apr 15:blood.2023022564. doi: 10.1182/blood.2023022564.
PubMed Abstract available

BULLINGER L, Kronke J
Making AML fly too close to the sun.
Blood. 2024;143:1438-1439.
PubMed

BOURGEOIS W, Cutler JA, Aubrey BJ, Wenge DV, et al
Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
Blood. 2024;143:1513-1527.
PubMed Abstract available

MARCAIS A
Targeting PD-L1 to treat ATLL?
Blood. 2024;143:1320-1322.
PubMed

MINA A, Greenberg PL, Deeg HJ
How I reduce and treat posttransplant relapse of MDS.
Blood. 2024;143:1344-1354.
PubMed Abstract available

BASTIAN L, Beder T, Barz MJ, Bendig S, et al
Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.
Blood. 2024;143:1391-1398.
PubMed Abstract available

March 2024

INESS AN, Bachireddy P
GPR56 in GVL: marker or mechanism?
Blood. 2024;143:1206-1207.
PubMed

MATHIOUDAKI A, Wang X, Sedloev D, Huth R, et al
The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature.
Blood. 2024;143:1269-1281.
PubMed Abstract available

BAUMGARTNER F, Baer C, Bamopoulos S, Ayoub E, et al
Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022.
Blood. 2024;143:1139-1156.
PubMed Abstract available

KLEIN K, Kollmann S, Hiesinger A, List J, et al
A lineage-specific STAT5BN642H mouse model to study NK-cell leukemia.
Blood. 2024 Mar 18:blood.2023022655. doi: 10.1182/blood.2023022655.
PubMed Abstract available

AZOULAY E, Maertens J, Lemiale V
How I manage acute respiratory failure in patients with hematological malignancies.
Blood. 2024;143:971-982.
PubMed Abstract available

MACK EA, Dougher MC, Ginda AM, Cahill C, et al
Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and leukostasis.
Blood. 2024;143:1049-1054.
PubMed Abstract available

FELIPE FUMERO E, Walter C, Frenz JM, Seifert FC, et al
Epigenetic control over cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia.
Blood. 2024 Mar 8:blood.2023021640. doi: 10.1182/blood.2023021640.
PubMed Abstract available

HAYASHI RJ, Hermiston ML, Wood BL, Teachey DT, et al
MRD at the End of Induction and EFS in T-cell Lymphoblastic Lymphoma: Children's Oncology Group Trial AALL1231.
Blood. 2024 Mar 8:blood.2023021184. doi: 10.1182/blood.2023021184.
PubMed Abstract available

CHALANDON Y, Rousselot P, Chevret S, Cayuela JM, et al
Nilotinib with or without cytarabine for Philadelphia positive acute lymphoblastic leukemia.
Blood. 2024 Mar 7:blood.2023023502. doi: 10.1182/blood.2023023502.
PubMed Abstract available

Colom Diaz PA, Mistry JJ, Trowbridge JJ. Hematopoietic stem cell aging and leukemia transformation. Blood. 2023;142(6):533-542.
Blood. 2024;143:939.
PubMed

AHMED R, Feldman AL
Occult ALK-negative anaplastic large cell lymphoma complicating chronic lymphocytic leukemia.
Blood. 2024;143:938.
PubMed

O'CONNOR D, Valle-Inclan JE, Conde L, Bloye G, et al
Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL.
Blood. 2024;143:933-937.
PubMed Abstract available

ESCHERICH CS, Chen W, Li Y, Yang W, et al
Germline Genetic NBN Variation and Predisposition to B-cell Acute Lymphoblastic Leukemia in Children.
Blood. 2024 Mar 6:blood.2023023336. doi: 10.1182/blood.2023023336.
PubMed Abstract available

AVILA AVILA A, Nuantang K, Oliveira ML, Druillennec S, et al
Targeting the TNF/IAP pathway synergizes with anti-CD3 immunotherapy in T-Cell Acute Lymphoblastic Leukemia.
Blood. 2024 Mar 4:blood.2023022455. doi: 10.1182/blood.2023022455.
PubMed Abstract available

February 2024

BARROS PINTO MP, Cabecadas J
Binucleated and cloverleaf-shaped nucleus in lymphocytes in CLL.
Blood. 2024;143:833.
PubMed

MURTADHA M, Park M, Zhu Y, Caserta E, et al
CD38-directed, single-chain T cell-engager targets leukemia stem cells through IFNgamma-induced CD38 expression.
Blood. 2024 Feb 26:blood.2023021570. doi: 10.1182/blood.2023021570.
PubMed Abstract available

VAN OUTERSTERP I, Tasian SK, Reichert CE, Boeree A, et al
Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: The role of kinase type and SH3 domain.
Blood. 2024 Feb 23:blood.2023023120. doi: 10.1182/blood.2023023120.
PubMed Abstract available

BARBOSA K, Deshpande A, Perales M, Xiang P, et al
Transcriptional control of leukemogenesis by the chromatin reader SGF29.
Blood. 2024;143:697-712.
PubMed Abstract available

BISWAS J, Abdel-Wahab O
A new SAGA for AML: targeting SGF29 in AML.
Blood. 2024;143:657-658.
PubMed

SUMMERS RJ, Teachey DT, Hunger SP
How I treat early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) in children.
Blood. 2024 Feb 16:blood.2023023155. doi: 10.1182/blood.2023023155.
PubMed Abstract available

MENSURADO S, Condeco AC, Sanchez-Martinez D, Shirley S, et al
CD155/PVR determines Acute Myeloid Leukemia targeting by Delta One T cells.
Blood. 2024 Feb 16:blood.2023022992. doi: 10.1182/blood.2023022992.
PubMed Abstract available

FISKUS W, Piel J, Collins MP, Hentemann M, et al
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor.
Blood. 2024 Feb 16:blood.2023022832. doi: 10.1182/blood.2023022832.
PubMed Abstract available

COTY-FATTAL Z, Richardson AI
A 3-year-old with chronic myeloid leukemia.
Blood. 2024;143:651.
PubMed

BARAJAS JM, Rasouli M, Umeda M, Hiltenbrand R, et al
Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors.
Blood. 2024;143:619-630.
PubMed Abstract available

BERNT KM
Menin dependence: UBTF-ITD AML joins the club.
Blood. 2024;143:567-569.
PubMed

CHEN B, Abdel-Wahab O
Targeting the cBAF complex in T-ALL.
Blood. 2024;143:566-567.
PubMed

ARBER C
Two to tango: engineered T cells against AML.
Blood. 2024;143:476-478.
PubMed

QIU L, Naresh KN
Mature plasmacytoid dendritic cell proliferation in association with mixed-phenotype acute leukemia, T/myeloid.
Blood. 2024;143:561.
PubMed

DAO T, Xiong G, Mun SS, Meyerberg J, et al
A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML.
Blood. 2024;143:507-521.
PubMed Abstract available

BHATT VR, Uy GL, Klepin HD
Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to action.
Blood. 2024;143:483-487.
PubMed Abstract available

ROUSSELOT P
Old rivals become new friends.
Blood. 2024;143:380-382.
PubMed

ORDONEZ MAZARIEGOS EE, Dimopoulos YP
A rare case of ICUS progressing to MDS with isolated isochromosome 17q and AML.
Blood. 2024;143:473.
PubMed

January 2024

GU H, Chen C, Hou ZS, He XD, et al
PI3Kgamma maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway.
Blood. 2024 Jan 25:blood.2023022202. doi: 10.1182/blood.2023022202.
PubMed Abstract available

SCHRAW JM
Anticancer drug exposure in utero and leukemia.
Blood. 2024;143:293-294.
PubMed

BARATA JT
Darwin, MSI2, and relapse in T-ALL.
Blood. 2024;143:294-296.
PubMed

SAHASRABUDHE KD, Mims AS
MRD in AML: who, what, when, where, and how?
Blood. 2024;143:296-298.
PubMed

OTHMAN J, Tiong IS, O'Nions J, Dennis M, et al
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.
Blood. 2024;143:336-341.
PubMed Abstract available

LEUNG WK, Torres Chavez AG, French-Kim M, Shafer P, et al
Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia.
Blood. 2024 Jan 19:blood.2023021979. doi: 10.1182/blood.2023021979.
PubMed Abstract available

WEINACHT KG
The rise of haplo: a quest for the perfect graft.
Blood. 2024;143:193-195.
PubMed

alphabetaT/CD19-depleted haploHSCT for pediatric leukemia.
Blood. 2024;143:291.
PubMed

CHEN H, Wang H
Acute myeloid leukemia with GATA2 and WT1 mutations mimicking acute promyelocytic leukemia.
Blood. 2024;143:290.
PubMed

SAULTIER P, Michel G
How I Treat: long-term survivors of childhood acute leukemia.
Blood. 2024 Jan 16:blood.2023019804. doi: 10.1182/blood.2023019804.
PubMed Abstract available

BULDINI B, Varotto E, Maurer-Granofszky M, Gaipa G, et al
CD371+ pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment.
Blood. 2024 Jan 12:blood.2023021952. doi: 10.1182/blood.2023021952.
PubMed Abstract available

Bamezai S, Pulikkottil AJ, Yadav T, et al. A noncanonical enzymatic function of PIWIL4 maintains genomic integrity and leukemic growth in AML. Blood. 2023;142(1):90-105.
Blood. 2024;143:184.
PubMed

DIMOPOULOS YP, Loghavi S
Acute leukemia of ambiguous lineage with BCL11B rearrangement.
Blood. 2024;143:183.
PubMed

GHORASHIAN S, Lucchini G, Richardson R, Nguyen K, et al
CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL.
Blood. 2024;143:118-123.
PubMed Abstract available

VELTMAAT L, Cortes J
Arterio-Occlusive Events Among Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitors.
Blood. 2024 Jan 9:blood.2023022403. doi: 10.1182/blood.2023022403.
PubMed Abstract available

MOSS P
Ibrutinib reversal of immune exhaustion in CLL.
Blood. 2024;143:5-7.
PubMed

Kennedy E, Coulter E, Halliwell E, et al. TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. Blood. 2021;137(22):3064-3078.
Blood. 2024;143:93.
PubMed

PAPAZOGLOU D, Wang XV, Shanafelt TD, Lesnick CE, et al
Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial.
Blood. 2024;143:57-63.
PubMed Abstract available

December 2023

QUESSADA J, Loosveld M
CBFB::MYH11 fusion in a nonmonocytic acute myeloid leukemia.
Blood. 2023;142:2332.
PubMed

HASSERJIAN RP, Germing U, Malcovati L
Diagnosis and classification of myelodysplastic syndromes.
Blood. 2023;142:2247-2257.
PubMed Abstract available

DEZERN AE, Greenberg PL
The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes.
Blood. 2023;142:2258-2267.
PubMed Abstract available

CHIBA M, Shimono J, Suto K, Ishio T, et al
Whole genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in Adult T-cell leukemia/lymphoma.
Blood. 2023 Dec 24:blood.2023021423. doi: 10.1182/blood.2023021423.
PubMed Abstract available

BRECCIA M
A traffic light for TFR by lineage-specific MRD.
Blood. 2023;142:2129-2130.
PubMed

FU L, Gong S
KMT2A-rearranged B-lymphoblastic leukemia/lymphoma with surface light chain restriction and lacking immature markers.
Blood. 2023;142:2220.
PubMed

NIH natural history study of FPDMM patients.
Blood. 2023;142:2222.
PubMed

FRANK D, Patnana PK, Vorwerk J, Mao L, et al
Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy.
Blood. 2023;142:2175-2191.
PubMed Abstract available

CUNNINGHAM L, Merguerian M, Calvo KR, Davis J, et al
Natural history study of patients with familial platelet disorder with associated myeloid malignancy.
Blood. 2023;142:2146-2158.
PubMed Abstract available

MARCELLINO BK
PPM1D inhibition may allow us to WIP leukemia.
Blood. 2023;142:2040-2042.
PubMed

COUSTAN-SMITH E, Conter V
Closing the circle for ETP ALL.
Blood. 2023;142:2039-2040.
PubMed

WOOD BL, Devidas M, Summers RJ, Chen Z, et al
Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study.
Blood. 2023;142:2069-2078.
PubMed Abstract available

DIMITRIOU M, Mortera-Blanco T, Tobiasson M, Mazzi S, et al
Identification and surveillance of rare relapse-initiating stem cells during complete remission post-transplantation.
Blood. 2023 Dec 14:blood.2023022851. doi: 10.1182/blood.2023022851.
PubMed Abstract available

PALM-APERGI C
PLK4, a potential target against AML.
Blood. 2023;142:1941-1942.
PubMed

STONE RM
FLT(3)-ing about: the search for the best inhibitor.
Blood. 2023;142:1937-1938.
PubMed

MAN CH, Lam W, Dang CC, Zeng XY, et al
Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML.
Blood. 2023;142:2002-2015.
PubMed Abstract available

FLEMING S, Tsai XC, Morris R, Hou HA, et al
TP53 status and impact on AML prognosis within the ELN 2022 risk classification.
Blood. 2023;142:2029-2033.
PubMed Abstract available

LOO S, Roberts AW, Anstee NS, Kennedy GA, et al
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.
Blood. 2023;142:1960-1971.
PubMed Abstract available

November 2023

BEWERSDORF JP, How J, Masarova L, Bose P, et al
Moving toward disease modification in polycythemia vera.
Blood. 2023;142:1859-1870.
PubMed Abstract available

DAVIDS MS
Functional cure reported in CLL.
Blood. 2023;142:1761-1763.
PubMed

LIN E, Chen W
Acute myeloid leukemia with NUP98::HOXA9 mimicking acute promyelocytic leukemia.
Blood. 2023;142:1845.
PubMed

Wei AH, Panayiotidis P, Montesinos P, et al. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy. Blood. 2022;140(25):2754-2756.
Blood. 2023;142:1846-1847.
PubMed

THOMPSON PA, Bazinet A, Wierda WG, Tam CS, et al
Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up.
Blood. 2023;142:1784-1788.
PubMed Abstract available

KIM R, Bergugnat H, Pastoret C, Pasquier F, et al
Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study.
Blood. 2023;142:1806-1817.
PubMed Abstract available

ROLLIG C
Gemtuzumab ozogamicin in AML: the next chapter.
Blood. 2023;142:1673-1674.
PubMed

STRASSER B, Haushofer A
Cabot rings in chronic myelomonocytic leukemia.
Blood. 2023;142:1757.
PubMed

FREEMAN SD, Thomas A, Thomas I, Hills RK, et al
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.
Blood. 2023;142:1697-1707.
PubMed Abstract available

Fractionated vs single-dose gemtuzumab for AML.
Blood. 2023;142:1759.
PubMed

BUENO C, Torres-Ruiz R, Velasco-Hernandez T, Molina O, et al
A human genome editing-based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features.
Blood. 2023;142:1752-1756.
PubMed Abstract available

THOL FR, Dohner H, Ganser A
How I treat refractory and relapsed acute myeloid leukemia.
Blood. 2023 Nov 9:blood.2023022481. doi: 10.1182/blood.2023022481.
PubMed Abstract available

VYAS P
Changing treatment changing prognosis of mutations.
Blood. 2023;142:1583-1585.
PubMed

AOKI K, Hyuga M, Tarumoto Y, Nishibuchi G, et al
Canonical BAF complex regulates the oncogenic program in human T-cell acute lymphoblastic leukemia.
Blood. 2023 Nov 3:blood.2023020857. doi: 10.1182/blood.2023020857.
PubMed Abstract available

October 2023

JABBOUR EJ, Haddad FG, Short NJ, Senapati J, et al
Phase II Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission.
Blood. 2023 Oct 25:blood.2023022330. doi: 10.1182/blood.2023022330.
PubMed Abstract available

MALAGA ML, Carrillo LF
FISH-negative, karyotype-negative acute promyelocytic leukemia.
Blood. 2023;142:1328.
PubMed

PRINCE HM
Blocked addiction to IL-15 for treating T-LGLL.
Blood. 2023;142:1258-1260.
PubMed

XIE J, Bao X, Xue SL, Shen H, et al
Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML.
Blood. 2023;142:1323-1327.
PubMed

ZHANG J, Duan Y, Wu P, Chang Y, et al
Clonal Evolution Dissection Reveals High MSI2 Level Promotes Chemo-resistance in T-cell Acute Lymphoblastic Leukemia.
Blood. 2023 Oct 6:blood.2023020490. doi: 10.1182/blood.2023020490.
PubMed Abstract available

KUMAR J, Petrova-Drus K
Acute leukemia with predominantly myeloid differentiation and TBL1XR1::CSF1R fusion.
Blood. 2023;142:1253.
PubMed

CHELOOR KOVILAKAM S, Gu M, Dunn WG, Marando L, et al
Prevalence and significance of DDX41 gene variants in the general population.
Blood. 2023;142:1185-1192.
PubMed Abstract available

YAMAMOTO S, Sanefuji M, Suzuki M, Sonoda Y, et al
Pediatric leukemia and maternal occupational exposure to anticancer drugs: The Japan Environment and Children's Study.
Blood. 2023 Oct 3:blood.2023021008. doi: 10.1182/blood.2023021008.
PubMed Abstract available

September 2023

GOEDE V
Frailty is also a target for targeted drugs in CLL.
Blood. 2023;142:1107-1108.
PubMed

VAN DER STRATEN L, Stege CAM, Kersting S, Nasserinejad K, et al
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL.
Blood. 2023;142:1131-1142.
PubMed Abstract available

MERLI P, Algeri M, Galaverna F, Bertaina V, et al
TCRalphabeta/CD19 cell-depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis.
Blood. 2023 Sep 22:blood.2023021336. doi: 10.1182/blood.2023021336.
PubMed Abstract available

LI S, Adams PD
Targeting the epichaperome to combat AML.
Blood. 2023;142:1031-1032.
PubMed

Gribben JG. Targeting the methylome to improve CLL outcome. Blood. 2023;142(1):4-6.
Blood. 2023;142:1103.
PubMed

CARTER BZ, Mak PY, Muftuoglu M, Tao W, et al
Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.
Blood. 2023;142:1056-1070.
PubMed Abstract available

UCKELMANN HJ, Klusmann JH
Double trouble: IRAK1/4 inhibitors in AML/MDS.
Blood. 2023;142:945-946.
PubMed

KWOK M, Stankovic T
CLL patients: GIVe me three!
Blood. 2023;142:941-943.
PubMed

HUBER H, Tausch E, Schneider C, Edenhofer S, et al
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Blood. 2023;142:961-972.
PubMed Abstract available

BENNETT J, Ishikawa C, Agarwal P, Yeung J, et al
Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML.
Blood. 2023;142:989-1007.
PubMed Abstract available

FEI MY, Wang Y, Chang BH, Xue K, et al
The non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment.
Blood. 2023;142:903-917.
PubMed Abstract available

August 2023

ZHANG Q, Li H, Chen X, Gu F, et al
Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia.
Blood. 2023 Aug 25:blood.2023020619. doi: 10.1182/blood.2023020619.
PubMed Abstract available

MELNICK AF, Mullin C, Lin K, McCarter AC, et al
Cdc73 protects Notch-induced T-cell leukemia cells from DNA damage and mitochondrial stress.
Blood. 2023 Aug 24:blood.2023020144. doi: 10.1182/blood.2023020144.
PubMed Abstract available

PAGANI IS, Shanmuganathan N, Dang P, Saunders VA, et al
Lineage-specific detection of residual disease predicts relapse in chronic myeloid leukemia patients stopping therapy.
Blood. 2023 Aug 24:blood.2023021119. doi: 10.1182/blood.2023021119.
PubMed Abstract available

RABIN KR
Insights into the genomics of iAMP21-ALL.
Blood. 2023;142:682-684.
PubMed

NIEMANN CU
BTK inhibitors: safety + efficacy = outcome.
Blood. 2023;142:679-680.
PubMed

MOLTENI E, Bono E, Galli A, Elena C, et al
Prevalence and clinical expression of germ line predisposition to myeloid neoplasms in adults with marrow hypocellularity.
Blood. 2023;142:643-657.
PubMed Abstract available

SEZAKI M, Huang G
Food for thought (and CML survival).
Blood. 2023;142:502-504.
PubMed

MULLIGAN SP
Karyotype and outcome in CLL.
Blood. 2023;142:402-404.
PubMed

Moujalled DM, Brown FC, Chua CC, et al. Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia. Blood. 2023;141(6):634-644.
Blood. 2023;142:494.
PubMed

Gaudio E, Paduano F, Ngankeu A, et al. Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas. Blood. 2013;121(2):351-359.
Blood. 2023;142:495.
PubMed

SENJO H, Harada S, Kubota SI, Tanaka Y, et al
Calcineurin inhibitor inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT.
Blood. 2023;142:477-492.
PubMed Abstract available

FURSTENAU M, Thus YJ, Robrecht S, Mellink CHM, et al
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Blood. 2023;142:446-459.
PubMed Abstract available

KHALSA JK, Cha J, Utro F, Naeem A, et al
Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples.
Blood. 2023;142:421-433.
PubMed Abstract available

July 2023

KOLIJN PM, Spath F, Khouja M, Hengeveld PJ, et al
Genetic drivers in the natural history of chronic lymphocytic leukemia development as early as 16 years before diagnosis.
Blood. 2023 Jul 31:blood.2023019609. doi: 10.1182/blood.2023019609.
PubMed Abstract available

SCHIMMER AD
ZDHHC21: a mitochondrial vulnerability in AML.
Blood. 2023;142:309-311.
PubMed

GOTTHARDT D
Targeting iron import to treat ANKL.
Blood. 2023;142:308-309.
PubMed

MORGAN KM, Sojitra P
Auer rod-like inclusions in chronic lymphocytic leukemia.
Blood. 2023;142:397.
PubMed

SHAO X, Xu A, Du W, Xu T, et al
The palmitoyltransferase ZDHHC21 regulates oxidative phosphorylation to induce differentiation block and stemness in AML.
Blood. 2023;142:365-381.
PubMed Abstract available

BOTTEN GA, Zhang Y, Dudnyk K, Kim YJ, et al
Structural variation cooperates with permissive chromatin to control enhancer hijacking-mediated oncogenic transcription.
Blood. 2023;142:336-351.
PubMed Abstract available

GRAMATGES MM
Poverty and health equity in childhood leukemia.
Blood. 2023;142:211-212.
PubMed

VELOSO A, Cools J
Targeting STAT5B in T-cell acute lymphoblastic leukemia.
Blood. 2023;142:215-217.
PubMed

VADAKEKOLATHU J, Rutella S
Escape from T-cell targeting immunotherapies in acute myeloid leukemia.
Blood. 2023 Jul 19:blood.2023019961. doi: 10.1182/blood.2023019961.
PubMed Abstract available

SENAPATI J, Urrutia S, Loghavi S, Short NJ, et al
Venetoclax Abrogates the Prognostic Impact of Splicing Factor Gene Mutations in Newly Diagnosed Acute Myeloid Leukemia.
Blood. 2023 Jul 13:blood.2023020649. doi: 10.1182/blood.2023020649.
PubMed Abstract available

FRIES C, Hermiston ML
Challenging T-ALL to IL-7Rp dual inhibition.
Blood. 2023;142:124-126.
PubMed

GU Z, Izraeli S
All about Down syndrome ALL.
Blood. 2023;142:126-128.
PubMed

DEL BUFALO F, Becilli M, Rosignoli C, De Angelis B, et al
Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL.
Blood. 2023;142:146-157.
PubMed Abstract available

GRIBBEN JG
Targeting the methylome to improve CLL outcome.
Blood. 2023;142:4-6.
PubMed

HODSON DJ
Breaking the loop in AML.
Blood. 2023;142:6-7.
PubMed

TORABI A, Naresh KN
T-cell prolymphocytic leukemia/lymphoma with TCRB::TCL1 translocation.
Blood. 2023;142:119.
PubMed

BAMEZAI S, Pulikkottil AJ, Yadav T, Vegi NM, et al
A noncanonical enzymatic function of PIWIL4 maintains genomic integrity and leukemic growth in AML.
Blood. 2023;142:90-105.
PubMed Abstract available

PARRY EM, Ten Hacken E, Wu CJ
Richter syndrome: novel insights into the biology of transformation.
Blood. 2023;142:11-22.
PubMed Abstract available

June 2023

SEYMOUR JF, Byrd JC, Ghia P, Kater AP, et al
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in ELEVATE-RR.
Blood. 2023 Jun 30:blood.2022018818. doi: 10.1182/blood.2022018818.
PubMed Abstract available

ROY N, Park CY
IL-34: a novel differentiation therapy for AML?
Blood. 2023;141:3130-3132.
PubMed

KUPPERS R
Targeting mRNA translation in CLL.
Blood. 2023;141:3129-3130.
PubMed

Itzykson R, Fournier E, Berthon C, et al. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood. 2021;138(7):507-519.
Blood. 2023;141:3233.
PubMed

Robin M, de Wreede LC, Padron E, et al. Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis. Blood. 2022;140(12):1408-1418.
Blood. 2023;141:3232-3233.
PubMed

THOMPSON PA, Tam CS
Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders.
Blood. 2023;141:3137-3142.
PubMed Abstract available

LARGEOT A, Klapp V, Viry E, Gonder S, et al
Inhibition of MYC translation through targeting of the newly identified PHB-eIF4F complex as a therapeutic strategy in CLL.
Blood. 2023;141:3166-3183.
PubMed Abstract available

BRAMMER JE, Ballen K, Sokol L, Querfeld C, et al
Effective Treatment with the Selective Cytokine Inhibitor BNZ-1 Reveals the Cytokine Dependency of T-LGL Leukemia.
Blood. 2023 Jun 23:blood.2022017643. doi: 10.1182/blood.2022017643.
PubMed Abstract available

STEEL K, Jamieson C
Getting to the core of ADAR2 activity in AML.
Blood. 2023;141:3014-3015.
PubMed

GUO M, Chan THM, Zhou Q, An O, et al
Core-binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis.
Blood. 2023;141:3078-3090.
PubMed Abstract available

YOSIFOV DY, Stilgenbauer S
Richter transformation: epigenetics to blame?
Blood. 2023;141:2915-2917.
PubMed

LAM WK, Yip SF
Cytopenic AML with marrow fibrosis and multihit TP53 abnormalities.
Blood. 2023;141:3006.
PubMed

TSAGIOPOULOU M, Chapaprieta V, Russinol N, Garcia-Torre B, et al
Chromatin activation profiling of stereotyped chronic lymphocytic leukemias reveals a subset 8-specific signature.
Blood. 2023;141:2955-2960.
PubMed Abstract available

BRAMLETT C, Eerdeng J, Jiang D, Lee Y, et al
RNA splicing factor Rbm25 underlies heterogeneous preleukemic clonal expansion in mice.
Blood. 2023;141:2961-2972.
PubMed Abstract available

GUOLLA L, Breitbart S, Foroutan F, Thabane L, et al
Impact of vincristine-steroid pulses during maintenance for B-cell pediatric ALL: a systematic review and meta-analysis.
Blood. 2023;141:2944-2954.
PubMed Abstract available

WLODARSKI MW
ERCC6L2 syndrome: attack of the TP53 clones.
Blood. 2023;141:2788-2789.
PubMed

EL CHAER F, Hourigan CS, Zeidan AM
How I treat AML incorporating the updated classifications and guidelines.
Blood. 2023;141:2813-2823.
PubMed Abstract available

ROSS DM
Single cells tell multiple tales in CML.
Blood. 2023;141:2668-2670.
PubMed

May 2023

TARIQ H, Davis A
Pediatric mixed phenotype acute leukemia, T/myeloid, with isolated FLT3 mutation.
Blood. 2023;141:2663.
PubMed

KIM MY
CXCR4 to improve both T cell homing and function.
Blood. 2023;141:2546-2547.
PubMed

GAO Q, Ryan SL, Iacobucci I, Ghate PS, et al
The genomic landscape of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21.
Blood. 2023 May 22:blood.2022019094. doi: 10.1182/blood.2022019094.
PubMed Abstract available

Trinh BQ, Ummarino S, Zhang Y, et al. Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML. Blood. 2021;138(15):1331-1344.
Blood. 2023;141:2542.
PubMed

QIU S, Sheth VS, Yan C, Liu J, et al
Metabolic Adaptation to Tyrosine Kinase Inhibition in Leukemia Stem Cells.
Blood. 2023 May 16:blood.2022018196. doi: 10.1182/blood.2022018196.
PubMed Abstract available

CHANG Y, Keramatnia F, Ghate PS, Nishiguchi G, et al
The orally bioavailable GSPT1/2 degrader SJ6986 exhibits in vivo efficacy in acute lymphoblastic leukemia.
Blood. 2023 May 12:blood.2022017813. doi: 10.1182/blood.2022017813.
PubMed Abstract available

WANG M
Targeting leukemia with a metabolic genotoxin.
Blood. 2023;141:2293-2295.
PubMed

DIAMOND B, Ziccheddu B, Maclachlan K, Taylor J, et al
Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures.
Blood. 2023;141:2359-2371.
PubMed Abstract available

KAMEDA K, Yanagiya R, Miyatake Y, Carreras J, et al
Hepatic niche leads to aggressive natural killer cell leukemia proliferation through transferrin-transferrin receptor 1 axis.
Blood. 2023 May 5:blood.2022018597. doi: 10.1182/blood.2022018597.
PubMed Abstract available

LEBECQUE B, Dannus LT
BCOR/BCORL1 mutated hypergranular cells mimicking acute promyelocytic leukemia.
Blood. 2023;141:2283.
PubMed

HUANG BJ, Shannon K
NFIA-ETO2, TP53, and erythroid leukemogenesis.
Blood. 2023;141:2168-2170.
PubMed

NIEMANN CU
Immediate COVID-19 treatment in CLL.
Blood. 2023;141:2167-2168.
PubMed

WEINBERG OK, Arber DA, Dohner H, Mullighan CG, et al
The International Consensus Classification of acute leukemias of ambiguous lineage.
Blood. 2023;141:2275-2277.
PubMed

April 2023

LAMBLE AJ, Hagiwara K, Gerbing RB, Smith JL, et al
CREBBP alterations are associated with a poor prognosis in de novo AML.
Blood. 2023;141:2156-2159.
PubMed

WADHWA A, Chen Y, Hageman L, Hoppmann A, et al
Poverty and Relapse Risk in Children with Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL03N1 Report.
Blood. 2023 Apr 17:blood.2023019631. doi: 10.1182/blood.2023019631.
PubMed Abstract available

RIBERA JM
T-ALL in CNS-3 status needs improvement.
Blood. 2023;141:1779-1780.
PubMed

USTUN C
Gold is gold even in mud: NPM1 mutations in T-AML.
Blood. 2023;141:1784-1785.
PubMed

WANG D, Sun Z, Zhu X, Zheng X, et al
Wang D, Sun Z, Zhu X, et al. GARP-mediated active TGF-beta1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT. Blood. 2022;140(26):2788-2804.
Blood. 2023;141:1896.
PubMed

Stein EM. IDH2 inhibition in AML. Blood. 2023;141(2):124-125.
Blood. 2023;141:1896.
PubMed

PENTER L, Liu Y, Wolff JO, Yang L, et al
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.
Blood. 2023;141:1817-1830.
PubMed Abstract available

OTHMAN J, Meggendorfer M, Tiacci E, Thiede C, et al
Overlapping features of therapy-related and de novo NPM1-mutated AML.
Blood. 2023;141:1846-1857.
PubMed Abstract available

GARCIA JS, Flamand Y, Penter L, Keng M, et al
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naive settings.
Blood. 2023;141:1884-1888.
PubMed

JIANG Q, Stachelscheid J, Bloehdorn J, Pacholewska A, et al
Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia.
Blood. 2023 Apr 6:blood.2022017230. doi: 10.1182/blood.2022017230.
PubMed Abstract available

COURTOIS L, Cabannes-Hamy A, Kim R, Delecourt M, et al
IL7-receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK-inhibition.
Blood. 2023 Apr 6:blood.2022017948. doi: 10.1182/blood.2022017948.
PubMed Abstract available

FALINI B, Lazzi S
B-cell prolymphocytic leukemia after COVID-19 infection.
Blood. 2023;141:1777.
PubMed

Bewersdorf JP, Patel KK, Goshua G, et al. Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia. Blood. 2022;139(11):1766-1770.
Blood. 2023;141:1778.
PubMed

DESHPANDE AJ, Zhu N
Silencing with SAFB: a new role for HOXA9 in AML.
Blood. 2023;141:1653-1655.
PubMed

BORNHAUSER M
T cells reloaded after allogeneic HCT.
Blood. 2023;141:1652-1653.
PubMed

DOLINSKA M, Cai H, Mansson A, Shen J, et al
Characterization of Bone Marrow Niche in Chronic Myeloid Leukemia Patients Identifies CXCL14 as a New Therapeutic Option.
Blood. 2023 Apr 5:blood.2022016896. doi: 10.1182/blood.2022016896.
PubMed Abstract available

SI LIM S, Ford JB, Hermiston ML
How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults.
Blood. 2023 Apr 5:blood.2022016503. doi: 10.1182/blood.2022016503.
PubMed Abstract available

ANJOS-AFONSO F, Bonnet D
Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level?
Blood. 2023 Apr 5:blood.2022018071. doi: 10.1182/blood.2022018071.
PubMed Abstract available

March 2023

LI Z, Chang TC, Junco JJ, Devidas M, et al
Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia.
Blood. 2023 Mar 31:blood.2023019765. doi: 10.1182/blood.2023019765.
PubMed Abstract available

XIE X, Zhang W, Xiao M, Wei T, et al
TREM2 acts as a receptor for IL-34 to suppress acute myeloid leukemia in mice.
Blood. 2023 Mar 31:blood.2022018619. doi: 10.1182/blood.2022018619.
PubMed Abstract available

HELMAN SR, Singh ZN
B-acute lymphoblastic leukemia with eosinophilic inclusions.
Blood. 2023;141:1645.
PubMed

BROWN FC, Wei AH
Is BCL-xL the Achilles' heel of AEL and AMKL?
Blood. 2023;141:1505-1506.
PubMed

PORTELINHA A, Wendel HG
The cat-and-mouse game of BTK inhibition.
Blood. 2023;141:1502-1503.
PubMed

CALVO J, Pflumio F
beta-Catenin and its new partner FOXO3 shake T-ALL.
Blood. 2023;141:1503-1505.
PubMed

Bonfiglio F, Bruscaggin A, Guidetti F, et al. Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood. 2022;139(5):732-747.
Blood. 2023;141:1647.
PubMed

MAKISHIMA H, Bowman TV, Godley LA
DDX41-associated susceptibility to myeloid neoplasms.
Blood. 2023;141:1544-1552.
PubMed Abstract available

ZHANG D, Harris HM, Chen J, Judy J, et al
NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts.
Blood. 2023;141:1584-1596.
PubMed Abstract available

TREMBLAY CS, Saw J, Boyle JA, Haigh K, et al
STAT5 activation promotes progression and chemotherapy-resistance in early T-cell precursor acute lymphoblastic leukemia.
Blood. 2023 Mar 29:blood.2022016322. doi: 10.1182/blood.2022016322.
PubMed Abstract available

HAKKARAINEN M, Kaaja I, Douglas SPM, Vulliamy TJ, et al
The Clinical Picture of the ERCC6L2 Disease - from Bone Marrow Failure to Acute Leukemia.
Blood. 2023 Mar 23:blood.2022019425. doi: 10.1182/blood.2022019425.
PubMed Abstract available

MEYER SE
Context is key for FLT3-ITD.
Blood. 2023;141:1373-1374.
PubMed

SAHASRABUDDHE AA, Elenitoba-Johnson KSJ
TCL1A expression promotes aggressive biology in CLL.
Blood. 2023;141:1371-1373.
PubMed

LI Y, Yang W, Patel RM, Casey EB, et al
FLT3ITD drives context-specific changes in cell identity and variable interferon dependence during AML initiation.
Blood. 2023;141:1442-1456.
PubMed Abstract available

STACHELSCHEID J, Jiang Q, Aszyk C, Warner K, et al
The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL.
Blood. 2023;141:1425-1441.
PubMed Abstract available

HEIMES DILLON AL, Kelting SM
Aggressive mast cell leukemia/sarcoma with CD4 expression and hemophagocytosis.
Blood. 2023;141:1364.
PubMed

Testi AM, Pession A, Diverio D, et al. Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. Blood. 2018;132(4):405-412.
Blood. 2023;141:1365.
PubMed

Lew TE, Tam CS, Seymour JF. How I treat chronic lymphocytic leukemia after venetoclax. Blood. 2021;138(5):361-369.
Blood. 2023;141:1366.
PubMed

SIMONIN M, Andrieu GP, Birsen R, Balsat M, et al
Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL.
Blood. 2023;141:1353-1358.
PubMed

SCHNEGG-KAUFMANN AS, Thoms JAI, Bhuyan GS, Hampton HR, et al
Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy.
Blood. 2023;141:1316-1321.
PubMed Abstract available

DAVER NG, Dail M, Garcia JS, Jonas BA, et al
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.
Blood. 2023;141:1265-1276.
PubMed Abstract available

NGAI LL, Hanekamp D, Janssen F, Carbaat-Ham J, et al
Prospective Validation of the Prognostic Relevance of CD34+CD38- AML Stem Cell frequency in the HOVON-SAKK132 trial.
Blood. 2023 Mar 10:blood.2022019160. doi: 10.1182/blood.2022019160.
PubMed

CHIHARA D
Synthetic lethality in ATL.
Blood. 2023;141:1096-1098.
PubMed

SMITH M
Harnessing ADR T cells to enhance allo-HCT.
Blood. 2023;141:1101-1102.
PubMed

GREVER MR
Two-inhibitor salvage therapy for hairy cell leukemia.
Blood. 2023;141:965-966.
PubMed

PFLUG N
T-LGLL: variety is the spice of this leukemia.
Blood. 2023;141:967-969.
PubMed

HIWASE D, Hahn C, Tran ENH, Chhetri R, et al
TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype.
Blood. 2023;141:1087-1091.
PubMed

PERIS I, Romero-Murillo S, Martinez-Balsalobre E, Farrington CC, et al
Activation of the PP2A-B56alpha heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation.
Blood. 2023;141:1047-1059.
PubMed Abstract available

ROAS M, Vick B, Kasper MA, Able M, et al
Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML.
Blood. 2023;141:1023-1035.
PubMed Abstract available

KRISHNAN V, Schmidt F, Nawaz Z, Venkatesh PN, et al
A Single-cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid Leukemia.
Blood. 2023 Mar 1:blood.2022017295. doi: 10.1182/blood.2022017295.
PubMed Abstract available

February 2023

TADMOR T, Alapi H, Rokach L
Effectiveness of nirmatrelvir plus ritonavir treatment for patients with CLL during the Omicron Surge.
Blood. 2023 Feb 27:blood.2022019017. doi: 10.1182/blood.2022019017.
PubMed Abstract available

GHALANDARY M, Gao Y, Amend D, Kutkaite G, et al
WT1 and DNMT3A play essential roles in the growth of certain patient AML cells in mice.
Blood. 2023;141:955-960.
PubMed

BANGHAM CRM
HTLV-1 persistence and the oncogenesis of adult T cell leukemia/lymphoma.
Blood. 2023 Feb 17:blood.2022019332. doi: 10.1182/blood.2022019332.
PubMed Abstract available

COLOM DIAZ PA, Mistry JJ, Trowbridge JJ
Hematopoietic Stem Cell Aging and Leukemia Transformation.
Blood. 2023 Feb 17:blood.2022017933. doi: 10.1182/blood.2022017933.
PubMed Abstract available

Hsu CA, Rishi AK, Su-Li X, et al. Retinoid induced apoptosis in leukemia cells through a retinoic acid nuclear receptor-independent pathway. Blood. 1997;89(12):4470-4479.
Blood. 2023;141:808.
PubMed

JIMENEZ A, Shuai W
BRAF-negative, CD103-negative hairy cell leukemia.
Blood. 2023;141:806.
PubMed

LENGLINE E
C1q helps AML to disseminate and resist.
Blood. 2023;141:691-692.
PubMed

RIBERA JM
JZP458 closes the asparaginase allergy gap.
Blood. 2023;141:685-686.
PubMed

ELITZUR S, Vora A, Burkhardt B, Inaba H, et al
EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy.
Blood. 2023;141:743-755.
PubMed Abstract available

BIONDI M, Tettamanti S, Galimberti S, Cerina B, et al
Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the Acute Myeloid Leukemia burden.
Blood. 2023 Feb 14:blood.2022018330. doi: 10.1182/blood.2022018330.
PubMed Abstract available

KIM WJ, Abdel-Wahab O
Acquired BAX mutations in AML.
Blood. 2023;141:562-564.
PubMed

NEWMAN H, Li Y, Liu H, Myers RM, et al
Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy.
Blood. 2023;141:609-619.
PubMed Abstract available

PATTERSON MT, Khan SM, Nunes NS, Fletcher RE, et al
Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects.
Blood. 2023;141:659-672.
PubMed Abstract available

PIQUE-BORRAS MR, Jevtic Z, Otzen Bagger F, Seguin J, et al
The NFIA-ETO2 fusion blocks erythroid maturation and induces pure erythroid leukemia in cooperation with mutant TP53.
Blood. 2023 Feb 3:blood.2022017273. doi: 10.1182/blood.2022017273.
PubMed Abstract available

LOPEZ CK, Mercher T
ERGonomics for EVI1 acute myeloid leukemia.
Blood. 2023;141:441-443.
PubMed

TRUONG P, Pimanda JE
DDX41: the poster child for familial MDS/AML grows up.
Blood. 2023;141:447-449.
PubMed

FERRERO S, Genuardi E
Looking for a needle in the haystack of CLL.
Blood. 2023;141:445-447.
PubMed

IYER SP
Newer insights on how to TEC down T-ALL.
Blood. 2023;141:444-445.
PubMed

MAKISHIMA H, Saiki R, Nannya Y, Korotev S, et al
Germ line DDX41 mutations define a unique subtype of myeloid neoplasms.
Blood. 2023;141:534-549.
PubMed Abstract available

SVATON M, Skotnicova A, Reznickova L, Rennerova A, et al
NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol.
Blood. 2023;141:529-533.
PubMed Abstract available

SCHMOELLERL J, Barbosa IAM, Minnich M, Andersch F, et al
EVI1 drives leukemogenesis through aberrant ERG activation.
Blood. 2023;141:453-466.
PubMed Abstract available

HENGEVELD PJ, van der Klift MY, Kolijn PM, Davi F, et al
Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL.
Blood. 2023;141:519-528.
PubMed Abstract available

January 2023

TAHIR SK, Calvo E, Carnero BA, Yuda J, et al
Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia.
Blood. 2023 Jan 30:blood.2022017333. doi: 10.1182/blood.2022017333.
PubMed Abstract available

ANGENENDT L, Rollig C, Montesinos P, Ravandi F, et al
Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification.
Blood. 2023;141:433-435.
PubMed

STURGESS KHM, Wilson NK, Gottgens B
Introduction to a review series on single-cell genomics: getting ready for clinical impact in leukemia and myeloid neoplasms.
Blood. 2023;141:323-325.
PubMed

EDIRIWICKREMA A, Gentles AJ, Majeti R
Single-cell genomics in AML: extending the frontiers of AML research.
Blood. 2023;141:345-355.
PubMed Abstract available

GANSER A
Role of allotransplantation in older patients with AML.
Blood. 2023;141:217-218.
PubMed

OLIVA-ARIZA G, Fuentes-Herrero B, Carbonell C, Lecrevisse Q, et al
High frequency of low-count monoclonal B-cell lymphocytosis in hospitalized COVID-19 patients.
Blood. 2023;141:309-314.
PubMed

LEE BC, Zhou Y, Bresciani E, Ozkaya N, et al
A RUNX1-FPDMM rhesus macaque model reproduces the human phenotype and predicts challenges to curative gene therapies.
Blood. 2023;141:231-237.
PubMed Abstract available

SORROR ML, Gooley TA, Storer BE, Gerds AT, et al
An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML.
Blood. 2023;141:295-308.
PubMed Abstract available

CHEN H, Bai Y, Kobayashi M, Xiao S, et al
PRL2 phosphatase enhances oncogenic FLT3 signaling via dephosphorylation of the E3 ubiquitin ligase CBL at tyrosine 371.
Blood. 2023;141:244-259.
PubMed Abstract available

DE BOTTON S, Montesinos P, Schuh AC, Papayannidis C, et al
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
Blood. 2023;141:156-167.
PubMed Abstract available

STEIN EM
IDH2 inhibition in AML.
Blood. 2023;141:124-125.
PubMed

RATTIGAN KM, Zarou MM, Helgason V
Metabolism in stem cell driven leukaemia: parallels between haematopoiesis and immunity.
Blood. 2023 Jan 12:blood.2022018258. doi: 10.1182/blood.2022018258.
PubMed Abstract available

GOSSAI N, Devidas M, Chen Z, Wood BL, et al
Central Nervous System Status is Prognostic in T-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report.
Blood. 2023 Jan 5:blood.2022018653. doi: 10.1182/blood.2022018653.
PubMed Abstract available

HEUCHON M, Wiber M
Cuplike nuclei in B-cell acute lymphoblastic leukemia with DUX4 rearrangement.
Blood. 2023;141:121.
PubMed

FRIEND BD
Treatment intensity in AML: a double-edged sword.
Blood. 2023;141:5-7.
PubMed

TURCOTTE LM, Whitton JA, Leisenring WM, Howell RM, et al
Chronic conditions, late mortality, and health status after childhood AML: a Childhood Cancer Survivor Study report.
Blood. 2023;141:90-101.
PubMed Abstract available

CLARKE ML, Lemma RB, Walton DS, Volpe G, et al
MYB insufficiency disrupts proteostasis in hematopoietic stem cells leading to age-related neoplasia.
Blood. 2023 Jan 5:blood.2022019138. doi: 10.1182/blood.2022019138.
PubMed Abstract available

MOES B, Li H, Molina-Ortiz P, Radermecker C, et al
INPP5K controls the dynamic structure and signaling of wild type and mutated, leukemia-associated IL7 receptors.
Blood. 2023 Jan 4:blood.2022017819. doi: 10.1182/blood.2022017819.
PubMed Abstract available

December 2022

VEKARIYA U, Toma MM, Nieborowska-Skorska M, Le BV, et al
DNA polymerase theta protects leukemia cells from metabolic-induced DNA damage.
Blood. 2022 Dec 29:blood.2022018428. doi: 10.1182/blood.2022018428.
PubMed Abstract available

KIM S, Choi J
Restoring NK cell functions in AML relapse.
Blood. 2022;140:2765-2766.
PubMed

WANG D, Sun Z, Zhu X, Zheng X, et al
GARP-mediated active TGF-beta1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT.
Blood. 2022;140:2788-2804.
PubMed Abstract available

AGRAWAL-SINGH S, Bagri J, Giotopoulos G, Azazi D, et al
HOXA9 forms a repressive complex with nuclear matrix-associated protein SAFB to maintain acute myeloid leukemia.
Blood. 2022 Dec 28:blood.2022016528. doi: 10.1182/blood.2022016528.
PubMed Abstract available

RIMANDO JC, Chendamarai E, Rettig MP, Jayasinghe RG, et al
Flotetuzumab and other T-Cell Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells.
Blood. 2022 Dec 23:blood.2022017795. doi: 10.1182/blood.2022017795.
PubMed Abstract available

MISHRA SK, Millman SE, Zhang L
Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets.
Blood. 2022 Dec 22:blood.2022018092. doi: 10.1182/blood.2022018092.
PubMed Abstract available

KOPMAR NE, Cassaday R
How I Prevent and Treat Central Nervous System Disease in Adults with Acute Lymphoblastic Leukemia.
Blood. 2022 Dec 22:blood.2022017035. doi: 10.1182/blood.2022017035.
PubMed Abstract available

DEARDEN C
It's a BRAF new world for hairy cell leukemia.
Blood. 2022;140:2649-2650.
PubMed

MELLINGHOFF SC, Cornely OA
SARS-CoV-2 vaccination in CLL: how often is enough?
Blood. 2022;140:2655-2657.
PubMed

SHEN Y, Freeman JA, Holland J, Naidu K, et al
Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion.
Blood. 2022;140:2709-2721.
PubMed Abstract available

WEI AH, Panayiotidis P, Montesinos P, Laribi K, et al
Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy.
Blood. 2022;140:2754-2756.
PubMed

FREIWAN A, Zoine JT, Crawford JC, Vaidya A, et al
Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies.
Blood. 2022;140:2684-2696.
PubMed Abstract available

BERTAINA A
Believe in haploidentical HSCT: less is better.
Blood. 2022;140:2523-2524.
PubMed

BRAUN T
An unexpected partnership targeting FLT3wt AML.
Blood. 2022;140:2529-2530.
PubMed

PULSIPHER MA, Ahn KW, Bunin NJ, Lalefar N, et al
KIR-favorable TCR-alphabeta/CD19-depleted haploidentical HCT in children with ALL/AML/MDS: primary analysis of the PTCTC ONC1401 trial.
Blood. 2022;140:2556-2572.
PubMed Abstract available

KUUSANMAKI H, Dufva O, Vaha-Koskela M, Leppa AM, et al
Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia.
Blood. 2022 Dec 12:blood.2021011094. doi: 10.1182/blood.2021011094.
PubMed Abstract available

GIALESAKI S, Brauer-Hartmann D, Issa H, Bhayadia R, et al
RUNX1 isoform disequilibrium promotes the development of trisomy 21 associated myeloid leukemia.
Blood. 2022 Dec 9:blood.2022017619. doi: 10.1182/blood.2022017619.
PubMed Abstract available

PRZESPOLEWSKI A, Goldberg AD, Talati C, Fazal S, et al
Safety and efficacy of CPX-351 in younger patients (< 60 years) with secondary acute myeloid leukemia.
Blood. 2022 Dec 9:blood.2022016678. doi: 10.1182/blood.2022016678.
PubMed

ZAHID MF, Kainthla R
Dinner-plate nuclei in hypogranular acute promyelocytic leukemia.
Blood. 2022;140:2519.
PubMed

RAHNAMA R, Bonifant CL
Engineering builds multipotency for iPSC-NKs.
Blood. 2022;140:2414-2416.
PubMed

CHIATTONE C, Alencar AJ
A balancing act between toxicity and deep response.
Blood. 2022;140:2309-2311.
PubMed

WANG QF, Zhu HH
APL: Nemo finds its sea anemone.
Blood. 2022;140:2311-2312.
PubMed

BLIXT L, Gao Y, Wullimann D, Muren Ingelman-Sundberg H, et al
Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination.
Blood. 2022;140:2403-2407.
PubMed

MARTINES C, Chakraborty S, Vujovikj M, Gobessi S, et al
Macrophage- and BCR-derived but not TLR-derived signals support the growth of CLL and Richter syndrome murine models in vivo.
Blood. 2022;140:2335-2347.
PubMed Abstract available

POPLINEAU M, Platet N, Mazuel A, Herault L, et al
Noncanonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias.
Blood. 2022;140:2358-2370.
PubMed Abstract available

LOO S, Dillon R, Ivey A, Anstee NS, et al
Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome.
Blood. 2022;140:2407-2411.
PubMed

SCARFO L, Heltai S, Albi E, Scarano E, et al
Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL.
Blood. 2022;140:2348-2357.
PubMed Abstract available

November 2022

CHITADZE G, Stengel A, John-Klaua C, Bruckmuller J, et al
Somatic TP53 mutations are pre-leukemic events in acute lymphoblastic leukemia.
Blood. 2022 Nov 30:blood.2022017249. doi: 10.1182/blood.2022017249.
PubMed

GHOBADI A, Slade M, Kantarjian H, Alvarenga J, et al
The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis.
Blood. 2022;140:2101-2112.
PubMed Abstract available

THIJSSEN R, Tian L, Anderson MA, Flensburg C, et al
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy.
Blood. 2022;140:2127-2141.
PubMed Abstract available

THOMALLA D, Beckmann L, Grimm C, Oliverio M, et al
Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies.
Blood. 2022;140:2113-2126.
PubMed Abstract available

DORES GM, Linet MS, Curtis RE, Morton LM, et al
Risks of therapy-related hematologic neoplasms beyond myelodysplastic syndromes and acute myeloid leukemia.
Blood. 2022 Nov 15. pii: 493239. doi: 10.1182/blood.2022018051.
PubMed

GALLIPOLI P
AML gets upSET when its dietary needs are unMet.
Blood. 2022;140:2003-2004.
PubMed

MURPHY WJ
Giving alloHSCT a needed LIF(t).
Blood. 2022;140:2008-2009.
PubMed

CHIBA M, Shimono J, Ishio T, Takei N, et al
Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas.
Blood. 2022;140:1951-1963.
PubMed Abstract available

YANG LX, Zhang CT, Yang MY, Zhang XH, et al
C1Q labels a highly aggressive macrophage-like leukemia population indicating extramedullary infiltration and relapse.
Blood. 2022 Nov 2. pii: 486969. doi: 10.1182/blood.2022017046.
PubMed Abstract available

October 2022

PANELLI P, De Santis E, Colucci M, Tamiro F, et al
Noncanonical beta-catenin interactions promote leukemia-initiating activity in early T-cell acute lymphoblastic leukemia.
Blood. 2022 Oct 31. pii: 486952. doi: 10.1182/blood.2022017079.
PubMed Abstract available

IACOBUCCI I, Mullighan CG
KMT2A-rearranged leukemia: the shapeshifter.
Blood. 2022;140:1833-1835.
PubMed

AL-ATTAR A, Woda BA
kappa light chain-expressing hematogones in a patient with lambda-restricted CLL and multiple myeloma on daratumumab therapy.
Blood. 2022;140:1917.
PubMed

WANG ES, Montesinos P, Minden MD, Lee JH, et al
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
Blood. 2022;140:1845-1857.
PubMed Abstract available

TIRTAKUSUMA R, Szoltysek K, Milne P, Grinev VV, et al
Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia.
Blood. 2022;140:1875-1890.
PubMed Abstract available

SHARMA M, Fu MP, Lu HY, Sharma AA, et al
Human complete NFAT1 deficiency causes a triad of joint contractures, osteochondromas, and B-cell malignancy.
Blood. 2022;140:1858-1874.
PubMed Abstract available

ZHAO L, Li S, Wei X, Qi X, et al
A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL.
Blood. 2022;140:1790-1802.
PubMed Abstract available

MARTI G
The clonal evolution and natural history of MBL.
Blood. 2022;140:1660-1661.
PubMed

SLAGER SL, Parikh SA, Achenbach SJ, Norman AD, et al
Progression and survival of MBL: a screening study of 10 139 individuals.
Blood. 2022;140:1702-1709.
PubMed Abstract available

DOHNER H, Wei AH, Roboz GJ, Montesinos P, et al
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
Blood. 2022;140:1674-1685.
PubMed Abstract available

MOUJALLED DM, Brown FC, Chua CC, Dengler MA, et al
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in Acute Myeloid Leukemia.
Blood. 2022 Oct 11. pii: 486781. doi: 10.1182/blood.2022016090.
PubMed Abstract available

KIPPS TJ
ROR1: an orphan becomes apparent.
Blood. 2022;140:1583-1591.
PubMed Abstract available

September 2022

RYLAND G, Umeda M, Holmfeldt L, Lehmann S, et al
Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions.
Blood. 2022 Sep 30. pii: 486718. doi: 10.1182/blood.2022017874.
PubMed

BERNT KM
Do you need the immune system to cure ALL?
Blood. 2022;140:1457-1458.
PubMed

Freeman SD, Valk P. Transplant in older adults with AML: genomic wheat and chaff. Blood. 2022;139(24):3459-3461.
Blood. 2022;140:1571.
PubMed

VAISITTI T, Vitale N, Micillo M, Brandimarte L, et al
Anti-CD37 alpha-amanitin-conjugated antibodies as potential therapeutic weapons for Richter syndrome.
Blood. 2022;140:1565-1569.
PubMed

IZUTSU K, Makita S, Nosaka K, Yoshimitsu M, et al
An Open-Label, Single-Arm, Phase 2 Trial of Valemetostat in Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma.
Blood. 2022 Sep 23. pii: 486703. doi: 10.1182/blood.2022016862.
PubMed Abstract available

SCHILLER G
How thinly can one slice the AML diagnostic pie?
Blood. 2022;140:1330-1331.
PubMed

GUINIPERO T, Kahwash SB
Morphologic findings often provide guidance when immunophenotypic data overlap: a case of AML with cup-shaped nuclei.
Blood. 2022;140:1448.
PubMed

DOHNER H, Wei AH, Appelbaum FR, Craddock C, et al
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.
Blood. 2022;140:1345-1377.
PubMed Abstract available

ZHANG M, Zhang H, Li Z, Bai L, et al
Functional, structural, and molecular characterizations of the leukemogenic driver MEF2D-HNRNPUL1 fusion.
Blood. 2022;140:1390-1407.
PubMed Abstract available

DUNCAVAGE EJ, Bagg A, Hasserjian RP, DiNardo CD, et al
Genomic Profiling for Clinical Decision Making in Myeloid Neoplasms and Acute Leukemia.
Blood. 2022 Sep 21. pii: 486675. doi: 10.1182/blood.2022015853.
PubMed Abstract available

KREITMAN RJ, Moreau P, Ravandi F, Hutchings M, et al
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.
Blood. 2022 Sep 15. pii: 486621. doi: 10.1182/blood.2021013658.
PubMed Abstract available

MAESE LD, Loh ML, Choi MR, Lin T, et al
Recombinant Erwinia Asparaginase (JZP458) in Acute Lymphoblastic Leukemia: Results from the Phase 2/3 AALL1931 Study.
Blood. 2022 Sep 15. pii: 486644. doi: 10.1182/blood.2022016923.
PubMed Abstract available

PENTER L, Wu CJ
AML relapse after a TIGIT race.
Blood. 2022;140:1189-1191.
PubMed

Duault C, Kumar A, Taghi Khani A, et al. Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia. Blood. 2021;138(16):1465-1480.
Blood. 2022;140:1326-1327.
PubMed

BARILA' G, Grassi A, Cheon H, Teramo A, et al
Tgammadelta LGL LEUKEMIA IDENTIFIES A SUBSET WITH MORE SYMPTOMATIC DISEASE: ANALYSIS OF AN INTERNATIONAL COHORT OF 137 PATIENTS.
Blood. 2022 Sep 12. pii: 486580. doi: 10.1182/blood.2021013489.
PubMed Abstract available

NAGLER A, Wu CJ
The end of the beginning: Application of single cell sequencing to chronic lymphocytic leukemia (CLL).
Blood. 2022 Sep 12. pii: 486574. doi: 10.1182/blood.2021014669.
PubMed Abstract available

WU HC, de The H
In APL, noncoding mutations and SNP converge on WT1.
Blood. 2022;140:1060-1061.
PubMed

PHILIPP N, Kazerani M, Nicholls A, Vick B, et al
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.
Blood. 2022;140:1104-1118.
PubMed Abstract available

August 2022

MO F, Watanabe N, Ingersoll Omdahl K, Burkhardt PM, et al
Engineering T cells to suppress acute GvHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation.
Blood. 2022 Aug 31. pii: 486464. doi: 10.1182/blood.2022016052.
PubMed Abstract available

KITTAI AS, Woyach JA
uMRD: "the" endpoint or "an" endpoint for CLL?
Blood. 2022;140:797-798.
PubMed

OBENG EA
Mutant SF3B1 splices a more leukemogenic EVI1.
Blood. 2022;140:800-801.
PubMed

SEYMOUR JF, Kipps TJ, Eichhorst BF, D'Rozario J, et al
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
Blood. 2022;140:839-850.
PubMed Abstract available

CUNNINGHAM A, Erdem A, Alshamleh I, Geugien M, et al
Dietary methionine starvation impairs acute myeloid leukemia progression.
Blood. 2022 Aug 19. pii: 486352. doi: 10.1182/blood.2022017575.
PubMed Abstract available

CAPPELLI LV, Fiore D, Phillip JM, Yoffe L, et al
Endothelial-leukemia interactions remodel drug responses uncovering T-ALL vulnerabilities.
Blood. 2022 Aug 18. pii: 486319. doi: 10.1182/blood.2022015414.
PubMed Abstract available

WANG J, Chang CY, Yang X, Zhou F, et al
Leukemia inhibitory factor protects against graft-versus-host disease while preserving graft-versus-leukemia activity.
Blood. 2022 Aug 18. pii: 486317. doi: 10.1182/blood.2022015677.
PubMed Abstract available

RIO-MACHIN A, Fitzgibbon J
DDX41: the poster child for familial AML.
Blood. 2022;140:667-669.
PubMed

LI P, Brown S, Williams M, White T, et al
The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms.
Blood. 2022;140:716-755.
PubMed Abstract available

WAGNER DL
The uncut version: base-edited allo-CAR T cells.
Blood. 2022;140:526-527.
PubMed

DEAGLIO S
Glutamine and CLL: ready for prime time?
Blood. 2022;140:528-529.
PubMed

DIORIO C, Murray R, Naniong M, Barrera L, et al
Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL.
Blood. 2022;140:619-629.
PubMed Abstract available

CARRATT SA, Kong GL, Curtiss BM, Schonrock Z, et al
Mutated SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms.
Blood. 2022;140:644-658.
PubMed Abstract available

HANDA S, Lee JO, Derkach A, Stone RM, et al
Long Term Outcomes in Patients with Relapsed or Refractory Hairy Cell Leukemia Treated with Vemurafenib Monotherapy.
Blood. 2022 Aug 5. pii: 486128. doi: 10.1182/blood.2022016183.
PubMed Abstract available

IACOBUCCI I, Witkowski MT, Mullighan CG
Single-cell analysis of acute lymphoblastic and lineage ambiguous leukemia - approaches and molecular insights.
Blood. 2022 Aug 4. pii: 486119. doi: 10.1182/blood.2022016954.
PubMed Abstract available

VOSO MT, Buccisano F
AML: making residual disease more measurable.
Blood. 2022;140:415-417.
PubMed

SCARFO L, Herishanu Y
CLL and COVID-19: light at the end of the tunnel?
Blood. 2022;140:407-409.
PubMed

LI SQ, Xu LP, Wang Y, Zhang XH, et al
An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study.
Blood. 2022;140:516-520.
PubMed

SHALABI H, Qin H, Su A, Yates B, et al
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.
Blood. 2022;140:451-463.
PubMed Abstract available

NIEMANN CU, da Cunha-Bang C, Helleberg M, Ostrowski SR, et al
Patients with CLL have a lower risk of death from COVID-19 in the Omicron era.
Blood. 2022;140:445-450.
PubMed Abstract available

CICHOCKI F, Goodridge J, Bjordahl R, Mahmood S, et al
Dual-antigen targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia.
Blood. 2022 Aug 2. pii: 486089. doi: 10.1182/blood.2021015184.
PubMed Abstract available

July 2022

VELASQUEZ MP, Mamonkin M
CD7 CAR: sword and shield.
Blood. 2022;140:293-294.
PubMed

GERDEMANN U, Alvarez-Calderon F
Uncovering CD4+ T-cell exhaustion in B-ALL.
Blood. 2022;140:294-296.
PubMed

LU P, Liu Y, Yang J, Zhang X, et al
Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial.
Blood. 2022;140:321-334.
PubMed Abstract available

BLACK GS, Huang X, Qiao Y, Tarapcsak S, et al
Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients.
Blood. 2022;140:401-405.
PubMed

KRAMER MH, Zhang Q, Sprung R, Day RB, et al
Proteomic and Phosphoproteomic Landscapes of Acute Myeloid Leukemia.
Blood. 2022 Jul 27. pii: 486036. doi: 10.1182/blood.2022016033.
PubMed Abstract available

ZEIDAN AM, Fenaux P, Gobbi M, Mayer J, et al
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy.
Blood. 2022;140:285-289.
PubMed

HO JG, Schmidt D, Lowinus T, Ryoo J, et al
Targeting MDM2 enhances anti-leukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation.
Blood. 2022 Jul 19. pii: 485955. doi: 10.1182/blood.2022016082.
PubMed Abstract available

EICHHORST B
Ibrutinib frontline in young patients with CLL.
Blood. 2022;140:80-81.
PubMed

XU K, Nacheva E
Secondary AML with MLL gene amplification.
Blood. 2022;140:161.
PubMed

SHANAFELT TD, Wang XV, Hanson CA, Paietta EM, et al
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
Blood. 2022;140:112-120.
PubMed Abstract available

JANSSEN M, Schmidt C, Bruch PM, Blank MF, et al
Venetoclax synergizes with Gilteritinib in FLT3 wildtype high-risk Acute Myeloid Leukemia by suppressing MCL-1.
Blood. 2022 Jul 13. pii: 485887. doi: 10.1182/blood.2021014241.
PubMed Abstract available

GOURNAY V, Vallet N, Peux V, Vera K, et al
Immune landscape after allo-HSCT: TIGIT and CD161-expressing CD4 T cells are associated with subsequent leukemia relapse.
Blood. 2022 Jul 12. pii: 485877. doi: 10.1182/blood.2022015522.
PubMed Abstract available

DIORIO C, Teachey DT
Please eat me! Targeting CD47 and CD38 in T-ALL.
Blood. 2022;140:6-8.
PubMed

GOWER M, Tikhonova AN
Avoiding fratricide: a T-ALL order.
Blood. 2022;140:3-4.
PubMed

HASSERJIAN RP
Revealing the dark secrets of TP53-mutated AML.
Blood. 2022;140:8-10.
PubMed

MULLER K, Vogiatzi F, Winterberg D, Rosner T, et al
Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL.
Blood. 2022;140:45-57.
PubMed Abstract available

June 2022

THAKRAL B, Bueso-Ramos CE
Unexpected presentation of cold agglutinin syndrome with B-acute lymphoblastic leukemia.
Blood. 2022;139:3778.
PubMed

BARTH BM
Ceramide: improving Bcl-2 inhibitor therapy.
Blood. 2022;139:3676-3678.
PubMed

WANG H, He X, Zhang L, Dong H, et al
Disruption of dNTP homeostasis by ribonucleotide reductase hyperactivation overcomes AML differentiation blockade.
Blood. 2022;139:3752-3770.
PubMed Abstract available

ARBER DA, Orazi A, Hasserjian RP, Borowitz MJ, et al
International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data.
Blood. 2022 Jun 29. pii: 485730. doi: 10.1182/blood.2022015850.
PubMed Abstract available

QIU L, Quesada AE
Plasma cell leukemia with small cell morphology.
Blood. 2022;139:3667.
PubMed

Al-Sawaf O, Lilienweiss E, Bahlo J, et al. High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia. Blood. 2020;135(11):866-870.
Blood. 2022;139:3669.
PubMed

TANAKA A, Nakano TA, Nomura M, Yamazaki H, et al
Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia.
Blood. 2022 Jun 16. pii: 485590. doi: 10.1182/blood.2021015325.
PubMed Abstract available

FIORETOS T
Why B(-)other? About the gap of unknowns in ALL.
Blood. 2022;139:3455-3457.
PubMed

FREEMAN SD, Valk P
Transplant in older adults with AML: genomic wheat and chaff.
Blood. 2022;139:3459-3461.
PubMed

Genetics and outcome in older AML transplant.
Blood. 2022;139:3559.
PubMed

YEUNG DT, Shanmuganathan N, Hughes TP
Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.
Blood. 2022;139:3474-3479.
PubMed Abstract available

PASSET M, Kim R, Gachet S, Sigaux F, et al
Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL.
Blood. 2022;139:3505-3518.
PubMed Abstract available

MURDOCK HM, Kim HT, Denlinger N, Vachhani P, et al
Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML.
Blood. 2022;139:3546-3557.
PubMed Abstract available

CHEMINANT M, Lhermitte L, Bruneau J, Sicard H, et al
KIR3DL2 contributes to the typing of acute-type adult T-cell leukemia and is a potential therapeutic target.
Blood. 2022 Jun 10. pii: 485527. doi: 10.1182/blood.2022016765.
PubMed Abstract available

ALVAREZ S, da Silva Almeida AC, Albero R, Biswas M, et al
Functional mapping of PHF6 complexes in chromatin remodeling, replication dynamics, and DNA repair.
Blood. 2022;139:3418-3429.
PubMed Abstract available

PERL AE, Larson RA, Podoltsev NA, Strickland S, et al
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
Blood. 2022;139:3366-3375.
PubMed Abstract available

LI Y, Yang X, Sun Y, Li Z, et al
The Impact of T cell Immunity on Chemotherapy Response in Childhood Acute Lymphoblastic Leukemia.
Blood. 2022 Jun 8. pii: 485490. doi: 10.1182/blood.2021014495.
PubMed Abstract available

ROBIN M, de Wreede LC, Padron E, Bakunina K, et al
Role of Allogeneic Transplantation In Chronic Myelomonocytic Leukemia: An International Collaborative Analysis.
Blood. 2022 Jun 6. pii: 485477. doi: 10.1182/blood.2021015173.
PubMed Abstract available

SONG H, Liu Y, Tan Y, Zhang Y, et al
Recurrent non-coding somatic and germline WT1 variants converge to disrupt MYB binding in acute promyelocytic leukemia.
Blood. 2022 Jun 2. pii: 485457. doi: 10.1182/blood.2021014945.
PubMed Abstract available

ROGERS KA, Woyach JA
A CAPTIVATE-ing new regimen for CLL.
Blood. 2022;139:3229-3230.
PubMed

FERNANDEZ-SEVILLA LM, Valencia J, Ortiz-Sanchez P, Fraile-Ramos A, et al
High BMP4 expression in low/intermediate risk BCP-ALL identifies children with poor outcomes.
Blood. 2022;139:3303-3313.
PubMed Abstract available

TAM CS, Allan JN, Siddiqi T, Kipps TJ, et al
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Blood. 2022;139:3278-3289.
PubMed Abstract available

May 2022

Genomic landscape of T-LGL leukemia.
Blood. 2022;139:3100.
PubMed

SEMENZATO G, Zambello R
Interrogating molecular genetics to refine LGLL classification.
Blood. 2022;139:3002-3004.
PubMed

LAUKKANEN S, Bacquelaine Veloso A, Yan C, Oksa L, et al
Combination therapies to inhibit LCK tyrosine kinase and mTOR signaling in T-cell Acute Lymphoblastic Leukemia.
Blood. 2022 May 11. pii: 485213. doi: 10.1182/blood.2021015106.
PubMed Abstract available

BIEDERSTADT A, Rezvani K
How I treat high-risk acute myeloid leukemia using pre-emptive adoptive cellular immunotherapy.
Blood. 2022 May 5. pii: 485176. doi: 10.1182/blood.2021012411.
PubMed Abstract available

Tomizawa D, Miyamura T, Imamura T, et al. A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial. Blood. 2020;136(16):1813-1823.
Blood. 2022;139:2848.
PubMed

LI L, Kim JH, Lu W, Williams DM, et al
HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression.
Blood. 2022;139:2797-2815.
PubMed Abstract available

TYAGI A, Ly S, El-Dana F, Yuan B, et al
Evidence supporting a role for the immune checkpoint protein B7-H3 in NK cell-mediated cytotoxicity against AML.
Blood. 2022;139:2782-2796.
PubMed Abstract available

FREY NV
Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia.
Blood. 2022 May 4. pii: 485154. doi: 10.1182/blood.2021014892.
PubMed Abstract available

MACIOCIA PM, Wawrzyniecka PA, Maciocia NC, Burley A, et al
Anti-CCR9 Chimeric Antigen Receptor T cells for T Cell Acute Lymphoblastic Leukemia.
Blood. 2022 May 4. pii: 485152. doi: 10.1182/blood.2021013648.
PubMed Abstract available

April 2022

CHEN Z, Simon-Molas H, Cretenet G, Valle-Argos B, et al
Characterization of metabolic alterations of Chronic Lymphocytic Leukemia in the lymph node microenvironment.
Blood. 2022 Apr 29. pii: 485126. doi: 10.1182/blood.2021013990.
PubMed Abstract available

BISHOP MR
New hope to prevent ALL relapse after transplant.
Blood. 2022;139:2580-2581.
PubMed

ZHAO Y, Wang E
Pure erythroid leukemia evolved from JAK2V617F-positive polycythemia vera: blast phase transformation along erythroid line.
Blood. 2022;139:2574.
PubMed

CHIANG MY
Firing up chromatin to forge T-ALL.
Blood. 2022;139:2418-2420.
PubMed

ANTOSZEWSKI M, Fournier N, Ruiz Buendia GA, Lourenco J, et al
Tcf1 is essential for initiation of oncogenic Notch1-driven chromatin topology in T-ALL.
Blood. 2022;139:2483-2498.
PubMed Abstract available

DUPLOYEZ N, Largeaud L, Duchmann M, Kim R, et al
Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study.
Blood. 2022 Apr 20. pii: 485005. doi: 10.1182/blood.2021015328.
PubMed Abstract available

LEWIS AC, Pope VS, Tea MN, Li M, et al
Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia.
Blood. 2022 Apr 20. pii: 485003. doi: 10.1182/blood.2021013277.
PubMed Abstract available

WELCH JS
TP53 and the star-crossed lovers MDS and AML.
Blood. 2022;139:2265-2266.
PubMed

TASHAKORI M, Kadia TM, Loghavi S, Daver NG, et al
TP53 Copy Number and Protein Expression Inform Mutation Status across Risk Categories in Acute Myeloid Leukemia.
Blood. 2022 Apr 7. pii: 484631. doi: 10.1182/blood.2021013983.
PubMed Abstract available

DANILOV AV
Immunity in CLL: corrupt at inception?
Blood. 2022;139:2104-2105.
PubMed

DEPASQUALE EAK, van Galen P
Plasticity and immune evasion in childhood ALL.
Blood. 2022;139:2096-2097.
PubMed

PURROY N, Tong YE, Lemvigh CK, Cieri N, et al
Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib.
Blood. 2022;139:2252-2256.
PubMed

ROBOZ GJ, Ravandi F, Wei AH, Dombret H, et al
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status.
Blood. 2022;139:2145-2155.
PubMed Abstract available

LEAHY AB, Devine KJ, Li Y, Liu H, et al
Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy.
Blood. 2022;139:2173-2185.
PubMed Abstract available

March 2022

BELLUSCI L, Grubbs G, Srivastava P, Nemeth MJ, et al
Neutralization of SARS-CoV-2 Omicron after vaccination of myelodysplastic syndromes and acute myeloid leukemia patients.
Blood. 2022 Mar 28. pii: 484507. doi: 10.1182/blood.2022016087.
PubMed

QI Y, Zhao M, Hu Y, Wang Y, et al
Efficacy and safety of CD19-specific CAR T-cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL.
Blood. 2022 Mar 25. pii: 484499. doi: 10.1182/blood.2021013733.
PubMed Abstract available

WANG HY, Heyman BM
Annexin A1- but CD10+ hairy cell leukemia.
Blood. 2022;139:1924.
PubMed

KATER AP, Melenhorst JJ
Do CARs finally hit the CLL road?
Blood. 2022;139:1775-1776.
PubMed

SIDDIQI T, Soumerai JD, Dorritie KA, Stephens DM, et al
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
Blood. 2022;139:1794-1806.
PubMed Abstract available

BUCHMANN S, Schrappe M, Baruchel A, Biondi A, et al
Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium.
Blood. 2022;139:1785-1793.
PubMed Abstract available

BEWERSDORF JP, Patel KK, Goshua G, Shallis RM, et al
Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia.
Blood. 2022;139:1766-1770.
PubMed

PARAS G, Morsink LM, Othus M, Milano F, et al
Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML.
Blood. 2022;139:1694-1706.
PubMed Abstract available

BEDNARSKI JJ, Zimmerman C, Berrien-Elliott MM, Foltz JA, et al
Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant.
Blood. 2022;139:1670-1683.
PubMed Abstract available

PARIHAR R
Memory NK cells to forget relapsed AML.
Blood. 2022;139:1607-1608.
PubMed

KLEPIN HD
Toward consensus on geriatric assessment in AML.
Blood. 2022;139:1605-1606.
PubMed

MIN GJ, Cho BS, Park SS, Park S, et al
Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML.
Blood. 2022;139:1646-1658.
PubMed Abstract available

TRACY SI, Venkatesh H, Hekim C, Heltemes Harris LM, et al
Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemia.
Blood. 2022 Mar 11. pii: 484383. doi: 10.1182/blood.2021015341.
PubMed Abstract available

MATSUOKA M
Targeting vulnerabilities of adult T-cell leukemia.
Blood. 2022;139:1435.
PubMed

NEDUMANNIL R, Juneja S
Pseudo-Chediak-Higashi inclusions in BCR::ABL1-like B-lymphoblastic leukemia with IGH::EPOR rearrangement.
Blood. 2022;139:1598.
PubMed

Silva O, Kurzer J. Nonleukemic T/B mixed phenotype acute leukemia with PHF6 and NOTCH1 mutations. Blood. 2021;138(9):818.
Blood. 2022;139:1602.
PubMed

MARTI G
Premonoclonal B-cell lymphocytosis: the CLL cell of origin.
Blood. 2022;139:1436-1437.
PubMed

STIVERS N, Afify Z
Pediatric B-acute lymphoblastic leukemia presenting with a mass: an underrecognized association.
Blood. 2022;139:1423.
PubMed

Awada H, Durmaz A, Gurnari C, et al. Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. Blood. 2021;138(19):1885-1895.
Blood. 2022;139:1424-1425.
PubMed

KWOK M, Stankovic T
The three musketeers: uniting against CLL.
Blood. 2022;139:1264-1265.
PubMed

VERRILLS NM
PP2A activation targets AML stem cells.
Blood. 2022;139:1267-1269.
PubMed

February 2022

MAITI A, Daver NG
A nonstick marrow may help to fry leukemia.
Blood. 2022;139:1119-1121.
PubMed

Lulla PD, Naik S, Vasileiou S, et al. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021;137(19):2585-2597.
Blood. 2022;139:1257.
PubMed

BROWN AL
And the germline beat (AML) goes on.
Blood. 2022;139:1126-1128.
PubMed

BERRIEN-ELLIOTT MM, Becker-Hapak M, Cashen AF, Jacobs M, et al
Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.
Blood. 2022;139:1177-1183.
PubMed Abstract available

YANG F, Long N, Anekpuritanang T, Bottomly D, et al
Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML.
Blood. 2022;139:1208-1221.
PubMed Abstract available

BLOMBERY P, Lew TE, Dengler MA, Thompson ER, et al
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
Blood. 2022;139:1198-1207.
PubMed Abstract available

SIPOL A, Hameister E, Xue B, Hofstetter J, et al
MondoA drives malignancy in B-ALL through enhanced adaptation to metabolic stress.
Blood. 2022;139:1184-1197.
PubMed Abstract available

KIMURA S, Montefiori L, Iacobucci I, Zhao Y, et al
Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia.
Blood. 2022 Feb 22. pii: 484108. doi: 10.1182/blood.2022015444.
PubMed Abstract available

BANGHAM CRM
Adult T-cell leukemia: genomic analysis.
Blood. 2022;139:953-954.
PubMed

YOU X, Liu F, Binder M, Vedder A, et al
Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
Blood. 2022;139:1066-1079.
PubMed Abstract available

CAZAUBIEL T, Leleu X, Perrot A, Manier S, et al
Primary Plasma Cell Leukemia displaying t(11;14) have specific genomic, transcriptional and clinical feature.
Blood. 2022 Feb 16. pii: 484066. doi: 10.1182/blood.2021014968.
PubMed Abstract available

FALINI B, De Carolis L, Tiacci E
How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors.
Blood. 2022 Feb 10. pii: 483952. doi: 10.1182/blood.2021013502.
PubMed Abstract available

WILL B
Fighting AML with its own weapons.
Blood. 2022;139:807-809.
PubMed

MILL CP, Fiskus W, DiNardo CD, Birdwell C, et al
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
Blood. 2022;139:907-921.
PubMed Abstract available

HEIKAMP EB, Henrich JA, Perner F, Wong EM, et al
The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML.
Blood. 2022;139:894-906.
PubMed Abstract available

NAIK S, Vasileiou S, Tzannou I, Kuvalekar M, et al
Donor-Derived Multiple Leukemia Antigen Specific T-cell Therapy to Prevent Relapse Post-Transplant in Patients with ALL.
Blood. 2022 Feb 8. pii: 483888. doi: 10.1182/blood.2021014648.
PubMed Abstract available

LV K, Tong W
Waking up CML leukemia stem cells for the kill.
Blood. 2022;139:647-648.
PubMed

WANG XQ, McGinnis E
Megakaryocytic emperipolesis as a dyshematopoietic feature in acute myeloid leukemia with inv(16).
Blood. 2022;139:798.
PubMed

BHAT SA, Woyach JA
Boosting BNT162b2 vaccine efficacy in CLL.
Blood. 2022;139:639-640.
PubMed

DEAGLIO S, Vaisitti T
A new taxonomy for splenic marginal zone lymphoma.
Blood. 2022;139:644-645.
PubMed

HERISHANU Y, Rahav G, Levi S, Braester A, et al
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.
Blood. 2022;139:678-685.
PubMed Abstract available

DAVIDS MS, Rogers KA, Tyekucheva S, Wang Z, et al
Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
Blood. 2022;139:686-689.
PubMed Abstract available

SASAKI K, Yamauchi T, Semba Y, Nogami J, et al
Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL.
Blood. 2022;139:748-760.
PubMed Abstract available

GROB T, Al Hinai AS, Sanders MA, Kavelaars F, et al
MOLECULAR CHARACTERIZATION OF MUTANT TP53 ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROME.
Blood. 2022 Feb 2. pii: 483799. doi: 10.1182/blood.2021014472.
PubMed Abstract available

January 2022

PETERS FS, Kater AP
Increasing CART cell engine performance in CLL.
Blood. 2022;139:473-474.
PubMed

FUNK CR, Wang S, Chen KZ, Waller A, et al
PI3Kdelta/gamma inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity.
Blood. 2022;139:523-537.
PubMed Abstract available

MAN CH, Mercier FE, Liu N, Dong W, et al
Proton export alkalinizes intracellular pH and reprograms carbon metabolism to drive normal and malignant cell growth.
Blood. 2022;139:502-522.
PubMed Abstract available

ABRAHAM IE, Rauscher GH, Patel AA, Pearse W, et al
Structural Racism is a Mediator of Disparities in Acute Myeloid Leukemia Outcomes.
Blood. 2022 Jan 21. pii: 483615. doi: 10.1182/blood.2021012830.
PubMed Abstract available

LEE EJ, Bussel JB
An "ATRA-ctive" new treatment of ITP?
Blood. 2022;139:307-308.
PubMed

SOMMERKAMP P, Trumpp A
Driving differentiation: targeting APA in AML.
Blood. 2022;139:317-319.
PubMed

MCCORMACK MP
T/myeloid MPAL: origin and pathogenesis.
Blood. 2022;139:313-315.
PubMed

AARAKAKI H, Karube K
Small-cell pattern of DUSP22 rearranged ALK-negative anaplastic large-cell lymphoma with leukemic phase.
Blood. 2022;139:465.
PubMed

ESTEY E, Hasserjian RP, Dohner H
Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal.
Blood. 2022;139:323-332.
PubMed Abstract available

WARREN AJ
Road to RIO-kinase 2 for AML therapy.
Blood. 2022;139:156-157.
PubMed

WANG W, Hu Z
Leukocytosis with left-shifted myeloid maturation in a peripheral blood specimen: a clue to the lymphoid blast phase of CML.
Blood. 2022;139:305.
PubMed

BRENDOLAN A, Russo V
Targeting cholesterol homeostasis in hematopoietic malignancies.
Blood. 2022;139:165-176.
PubMed Abstract available

FUJIHARA M, Sakata R, Yoshida N, Ozasa K, et al
Incidence of lymphoid neoplasms among atomic bomb survivors by histological subtype, 1950 to 1994.
Blood. 2022;139:217-227.
PubMed Abstract available

CHEON H, Xing JC, Moosic KB, Ung J, et al
Genomic Landscape of TCR Alpha-Beta and TCR Gamma-Delta T-Large Granular Lymphocyte Leukemia.
Blood. 2022 Jan 11. pii: 483429. doi: 10.1182/blood.2021013164.
PubMed Abstract available

ZHANG YH, Han X
Acute promyelocytic leukemia with Chediak-Higashi like giant granules.
Blood. 2022;139:149.
PubMed

BULLINGER L
CEBPA mutations in AML: site matters.
Blood. 2022;139:6-7.
PubMed

YOUNG PE, Medeiros LJ
Unexpected myeloid sarcoma of the tonsil in a patient without a history of hematological neoplasm.
Blood. 2022;139:148.
PubMed

December 2021

VOLK A
Ticket to divide: m6A reader YTHDC1 drives acute myeloid leukemia proliferation.
Blood. 2021;138:2748-2750.
PubMed

MORENO C, Mora A
MRD in CLL: some answers, many questions.
Blood. 2021;138:2746-2747.
PubMed

TRAN A, Wong M
Atypical CML with mutated SRSF2, ASXL1, CSF3R, and MPL.
Blood. 2021;138:2890.
PubMed

WANG XV, Hanson CA, Tschumper RC, Lesnick CE, et al
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Blood. 2021;138:2810-2827.
PubMed Abstract available

SHENG Y, Wei J, Yu F, Xu H, et al
A critical role of nuclear m6A reader YTHDC1 in leukemogenesis by regulating MCM complex-mediated DNA replication.
Blood. 2021;138:2838-2852.
PubMed Abstract available

CAI H, Kondo M, Sandhow L, Xiao P, et al
Critical Role of Lama4 for Hematopoiesis Regeneration and Acute Myeloid Leukemia Progression.
Blood. 2021 Dec 27. pii: 483253. doi: 10.1182/blood.2021011510.
PubMed Abstract available

POZDNYAKOVA O
NPM1: not present? Mark!
Blood. 2021;138:2602-2603.
PubMed

AL-SAWAF O, Fischer K
TP53 mutations in CLL: does frequency matter?
Blood. 2021;138:2600-2601.
PubMed

UY GL
Turning AML targets inside out.
Blood. 2021;138:2598-2599.
PubMed

TEN HACKEN E, Wu CJ
Understanding CLL biology through mouse models of human genetics.
Blood. 2021;138:2621-2631.
PubMed Abstract available

RIGOLIN GM, Del Giudice I, Bardi A, Melandri A, et al
Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study.
Blood. 2021;138:2727-2730.
PubMed

MARTELLI MP, Rossi R, Venanzi A, Meggendorfer M, et al
Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML.
Blood. 2021;138:2696-2701.
PubMed Abstract available

AUGSBERGER C, Hanel G, Xu W, Pulko V, et al
Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.
Blood. 2021;138:2655-2669.
PubMed Abstract available

MALCIKOVA J, Pavlova S, Barbara KV, Radova L, et al
Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.
Blood. 2021;138:2670-2685.
PubMed Abstract available

GABALLA MR, Banerjee PP, Milton DR, Jiang X, et al
Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia.
Blood. 2021 Dec 16. pii: 483090. doi: 10.1182/blood.2021013290.
PubMed Abstract available

SHOPSOWITZ KE, Slack GW
B-lymphoblastic lymphoma presenting as a primary breast mass with periductal invasion.
Blood. 2021;138:2593.
PubMed

SIVINA M, Kim E, Wierda WG, Ferrajoli A, et al
Ibrutinib induces durable remissions in treatment-naive patients with CLL and 17p deletion and/or TP53 mutations.
Blood. 2021;138:2589-2592.
PubMed

TONC E, Takeuchi Y, Chou C, Xia Y, et al
Unexpected suppression of tumorigenesis by c-MYC via TFAP4-dependent restriction of stemness in B lymphocytes.
Blood. 2021;138:2526-2538.
PubMed Abstract available

HUBER H, Edenhofer S, von Tresckow J, Robrecht S, et al
Phase 2 study of obinutuzumab (GA-101), ibrutinib and venetoclax (CLL2-GIVe) in patients with untreated high-risk chronic lymphocytic leukemia.
Blood. 2021 Dec 15. pii: 483086. doi: 10.1182/blood.2021013208.
PubMed Abstract available

ROSENQUIST R
The more complex, the worse outcome in CLL.
Blood. 2021;138:2305-2307.
PubMed

THAKRAL B, Lin P
Acute myeloid leukemia with erythroid and megakaryocytic differentiation associated with Down syndrome.
Blood. 2021;138:2446.
PubMed

HITZLER J, Alonzo T, Gerbing R, Beckman A, et al
High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial.
Blood. 2021;138:2337-2346.
PubMed Abstract available

KITTAI AS, Miller C, Goldstein D, Huang Y, et al
The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib.
Blood. 2021;138:2372-2382.
PubMed Abstract available

LI Y, Xie X, Jie Z, Zhu L, et al
DYRK1a mediates BAFF-induced noncanonical NF-kappaB activation to promote autoimmunity and B-cell leukemogenesis.
Blood. 2021;138:2360-2371.
PubMed Abstract available

WEEKS LD, Marinac CR, Redd RA, Abel GA, et al
Age-related Diseases of Inflammation in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia.
Blood. 2021 Dec 7. pii: 482919. doi: 10.1182/blood.2021014418.
PubMed

CHEN C, Yu W, Alikarami F, Qiu Q, et al
Single-cell multiomics reveals increased plasticity, resistant populations and stem-cell-like blasts in KMT2A-rearranged leukemia.
Blood. 2021 Dec 5. pii: 482898. doi: 10.1182/blood.2021013442.
PubMed Abstract available

BHATIA R
Fattening up FLT3-ITD for the kill.
Blood. 2021;138:2158-2159.
PubMed

November 2021

SCHWALLER J
MLL-AF4+ infant leukemia: a microRNA affair.
Blood. 2021;138:2014-2015.
PubMed

JACOBS JW, Siddon AJ
Concurrent COVID-19 and babesiosis in an older, splenectomized patient.
Blood. 2021;138:2154.
PubMed

REA D, Mauro MJ, Boquimpani C, Minami Y, et al
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Blood. 2021;138:2031-2041.
PubMed Abstract available

ROSSI M, Meggendorfer M, Zampini M, Tettamanti M, et al
Clinical relevance of clonal hematopoiesis in persons aged >/=80 years.
Blood. 2021;138:2093-2105.
PubMed Abstract available

MARCAULT C, Zhao LP, Maslah N, Verger E, et al
Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms.
Blood. 2021;138:2142-2148.
PubMed

ISHIO T, Kumar S, Shimono J, Daenthanasanmak A, et al
Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in Adult T-cell leukemia/lymphoma.
Blood. 2021 Nov 24. pii: 482776. doi: 10.1182/blood.2021012734.
PubMed Abstract available

ZHONG W, Cao X, Pan G, Niu Q, et al
ORP4L is a prerequisite for the induction of T-cell leukemogenesis associated with human T-cell leukemia virus 1.
Blood. 2021 Nov 19. pii: 482705. doi: 10.1182/blood.2021013579.
PubMed Abstract available

GOSWAMI S, Mani R, Nunes J, Chiang CL, et al
PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in Acute Myeloid Leukemia.
Blood. 2021 Nov 17. pii: 482661. doi: 10.1182/blood.2020010344.
PubMed Abstract available

ZHAO H, Pomicter AD, Eiring AM, Franzini A, et al
MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia by Enhancing Common beta Chain Cytokine Receptor Endocytosis.
Blood. 2021 Nov 15. pii: 477970. doi: 10.1182/blood.2021011802.
PubMed Abstract available

THOMAS D
Machine learning finds new AML subtypes.
Blood. 2021;138:1790-1792.
PubMed

DE BOCK CE, Cools J
BETter insight into PRC2-mutated T-ALL.
Blood. 2021;138:1787-1788.
PubMed

CHOI MY
Improving the outlook for TP53-aberrant CLL.
Blood. 2021;138:1785-1786.
PubMed

ANDRIEU GP, Kohn M, Simonin M, Smith CL, et al
PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL.
Blood. 2021;138:1855-1869.
PubMed Abstract available

CRAMER P, Tausch E, von Tresckow J, Giza A, et al
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Blood. 2021;138:1805-1816.
PubMed Abstract available

MHIBIK M, Gaglione EM, Eik D, Kendall EK, et al
BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.
Blood. 2021;138:1843-1854.
PubMed Abstract available

LANGERBEINS P, Zhang C, Robrecht S, Cramer P, et al
The CLL12 trial: Ibrutinib versus placebo in treatment-naive, early stage chronic lymphocytic leukemia.
Blood. 2021 Nov 10. pii: 477942. doi: 10.1182/blood.2021010845.
PubMed Abstract available

HASLE H, Kline RM, Kjeldsen E, Nik-Abdul-Rashid NF, et al
Germline GATA1s generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype.
Blood. 2021 Nov 10. pii: 477943. doi: 10.1182/blood.2021011463.
PubMed Abstract available

FENG Y, Feng W
Numerous ring sideroblasts in chronic neutrophilic leukemia.
Blood. 2021;138:1783.
PubMed

HERISHANU Y, Perry C
COVID-19 in patients with CLL: how can we change the odds?
Blood. 2021;138:1652-1653.
PubMed

ROEKER LE, Eyre TA, Thompson MC, Lamanna N, et al
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.
Blood. 2021;138:1768-1773.
PubMed

HEUSER M, Freeman SD, Ossenkoppele GJ, Buccisano F, et al
2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document.
Blood. 2021 Nov 1. pii: 477736. doi: 10.1182/blood.2021013626.
PubMed Abstract available

October 2021

CARTER BZ, Tao W, Mak PY, Ostermann LB, et al
Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML.
Blood. 2021;138:1637-1641.
PubMed

KOGURE Y, Kameda T, Koya J, Yoshimitsu M, et al
Whole-genome landscape of adult T-cell leukemia/lymphoma.
Blood. 2021 Oct 25. pii: S0006-4971(21)01784-5. doi: 10.1182/blood.2021013568.
PubMed Abstract available

SCHNOEDER TM, Schwarzer A, Jayavelu AK, Hsu CJ, et al
PLCG1 is required for AML1-ETO leukemia stem cell self-renewal.
Blood. 2021 Oct 25. pii: S0006-4971(21)01783-3. doi: 10.1182/blood.2021012778.
PubMed Abstract available

YASUDA T, Sanada M, Kawazu M, Kojima S, et al
Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations.
Blood. 2021 Oct 25. pii: S0006-4971(21)01785-7. doi: 10.1182/blood.2021011921.
PubMed Abstract available

ZHAO Y, Wang E
Plasmablastic myeloma/leukemia variant of monomorphic posttransplant lymphoproliferative disorder.
Blood. 2021;138:1510.
PubMed

HAUER J, Fischer U, Borkhardt A
Toward prevention of childhood ALL by early-life immune training.
Blood. 2021;138:1412-1428.
PubMed Abstract available

JEBARAJ BMC, Muller A, Dheenadayalan RP, Endres S, et al
Evaluation of vecabrutinib as a model for non-covalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia.
Blood. 2021 Oct 18. pii: 477372. doi: 10.1182/blood.2021011516.
PubMed Abstract available

KOLIJN PMM, Saberi Hosnijeh F, Spath F, Hengeveld PJ, et al
HIGH-RISK SUBTYPES OF CHRONIC LYMPHOCYTIC LEUKEMIA ARE DETECTABLE AS EARLY AS 16 YEARS PRIOR TO DIAGNOSIS.
Blood. 2021 Oct 18. pii: 477373. doi: 10.1182/blood.2021012890.
PubMed Abstract available

TRINH BQ, Ummarino S, Zhang Y, Ebralidze AK, et al
Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML.
Blood. 2021;138:1331-1344.
PubMed Abstract available

FISHMAN H, Madiwale S, Geron I, Bari V, et al
ETV6-NCOA2 fusion induces T/Myeloid mixed-phenotype leukemia by transformation of non-thymic hematopoietic progenitors.
Blood. 2021 Oct 8. pii: 477216. doi: 10.1182/blood.2020010405.
PubMed Abstract available

PROSSER AL, Li W
Salmon-colored granules in the leukemic blasts of B-lymphoblastic leukemia with iAMP21.
Blood. 2021;138:1282.
PubMed

September 2021

SIERRA J, Nomdedeu JF
CEBPA bZip mutations: just a single shot.
Blood. 2021;138:1091-1092.
PubMed

XU D, Naresh KN
Leukemic presentation of a highly aggressive ALK-negative anaplastic large cell lymphoma.
Blood. 2021;138:1198.
PubMed

STEPHENS DM, Byrd JC
Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.
Blood. 2021;138:1099-1109.
PubMed Abstract available

TARLOCK K, Lamble AJ, Wang YC, Gerbing RB, et al
CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.
Blood. 2021;138:1137-1147.
PubMed Abstract available

ALEJO-VALLE O, Weigert K, Bhayadia R, Ng M, et al
The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis.
Blood. 2021 Sep 27. pii: 477055. doi: 10.1182/blood.2021012231.
PubMed Abstract available

PALLASCH CP
Cell cycle control in Richter transformation.
Blood. 2021;138:1005-1007.
PubMed

HAN C, Ntziachristos P
T-ALL and the talented Mr IL7Ralpha.
Blood. 2021;138:1003-1004.
PubMed

YU X, Munoz-Sagredo L, Streule K, Muschong P, et al
CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues.
Blood. 2021;138:1067-1080.
PubMed Abstract available

CHAKRABORTY S, Martines C, Porro F, Fortunati I, et al
B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation.
Blood. 2021;138:1053-1066.
PubMed Abstract available

DEANGELO DJ, Jonas BA, Liesveld JL, Bixby DL, et al
Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia.
Blood. 2021 Sep 20. pii: 476977. doi: 10.1182/blood.2021010721.
PubMed Abstract available

BERMAN E
How I Treat Chronic Phase Chronic Myelogenous Leukemia.
Blood. 2021 Sep 16. pii: 476939. doi: 10.1182/blood.2021011722.
PubMed Abstract available

PAIETTA E, Roberts KG, Wang V, Gu Z, et al
Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL.
Blood. 2021;138:948-958.
PubMed Abstract available

AMAYA M, Inguva A, Pei S, Jones CL, et al
The STAT3-MYC Axis Promotes Survival of Leukemia Stem Cells by Regulating SLC1A5 and Oxidative Phosphorylation.
Blood. 2021 Sep 15. pii: 476917. doi: 10.1182/blood.2021013201.
PubMed Abstract available

SAMARAWEERA SE, Wang PP, Li KL, Casolari DA, et al
Childhood Acute Myeloid Leukemia shows a high level of germline predisposition.
Blood. 2021 Sep 14. pii: 476894. doi: 10.1182/blood.2021012666.
PubMed

ROSSOFF J, Baggott C, Prabhu S, Pacenta HL, et al
Out of Specification Tisagenlecleucel Does Not Compromise Safety or Efficacy in Pediatric Acute Lymphoblastic Leukemia.
Blood. 2021 Sep 9. pii: 476839. doi: 10.1182/blood.2021012392.
PubMed

MA S, Seymour JF, Brander DM, Kipps TJ, et al
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy.
Blood. 2021;138:836-846.
PubMed Abstract available

DAVIS AG, Johnson DT, Zheng D, Wang R, et al
Alternative polyadenylation dysregulation contributes to the differentiation block of acute myeloid leukemia.
Blood. 2021 Sep 5. pii: 476791. doi: 10.1182/blood.2020005693.
PubMed Abstract available

MEIJERINK JPP
BCL11B, the Cerberus of human leukemia.
Blood. 2021;138:741-743.
PubMed

SILVA O, Kurzer J
Nonleukemic T/B mixed phenotype acute leukemia with PHF6 and NOTCH1 mutations.
Blood. 2021;138:818.
PubMed

IMGRUET MK, Lutze J, An N, Hu B, et al
Loss of a 7q gene, CUX1, disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms.
Blood. 2021;138:790-805.
PubMed Abstract available

August 2021

HERLING M, Wahnschaffe L
Altered epigenetics at the center of NK-LGL leukemia.
Blood. 2021;138:589-591.
PubMed

WHEAT JC, Steidl U
Gene expression at a single-molecule level: implications for myelodysplastic syndromes and acute myeloid leukemia.
Blood. 2021;138:625-636.
PubMed Abstract available

JANN JC, Tothova Z
Cohesin mutations in myeloid malignancies.
Blood. 2021;138:649-661.
PubMed Abstract available

QING Y, Su R, Chen J
RNA modifications in hematopoietic malignancies: a new research frontier.
Blood. 2021;138:637-648.
PubMed Abstract available

MESSLING JE, Agger K, Andersen KL, Kromer K, et al
Targeting RIOK2 ATPase activity leads to decreased protein synthesis and cell death in acute myeloid leukemia.
Blood. 2021 Aug 25. pii: 476529. doi: 10.1182/blood.2021012629.
PubMed Abstract available

ASTOLFI A, Masetti R, Indio V, Bertuccio SN, et al
Torque Teno Mini Virus as a cause of childhood acute promyelocytic leukemia lacking PML/RARA fusion.
Blood. 2021 Aug 25. pii: 476664. doi: 10.1182/blood.2021011677.
PubMed

ZANETTI C, Kumar R, Ender J, Godavarthy PS, et al
The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13.
Blood. 2021 Aug 23. pii: 476652. doi: 10.1182/blood.2021011557.
PubMed Abstract available

DERECKA M
AML onco-niche: villain or ally?
Blood. 2021;138:504-506.
PubMed

BURGER JA
CLL cells are moved by the MARCKS brothers.
Blood. 2021;138:503-504.
PubMed

SCHILLER G
A slow-go prognosis for older patients with newly diagnosed AML.
Blood. 2021;138:501-502.
PubMed

Genetic decision model for fit older AML patients.
Blood. 2021;138:585.
PubMed

ITZYKSON R, Fournier E, Berthon C, Rollig C, et al
Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy.
Blood. 2021;138:507-519.
PubMed Abstract available

WUDHIKARN K, Flynn JR, Riviere I, Gonen M, et al
Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy.
Blood. 2021;138:531-543.
PubMed Abstract available

BECKMANN L, Berg V, Dickhut C, Sun C, et al
MARCKS affects cell motility and response to BTK inhibitors in CLL.
Blood. 2021;138:544-556.
PubMed Abstract available

CORTES J, Apperley JF, Lomaia E, Moiraghi B, et al
Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia: A Randomized, Open-Label Phase 2 Clinical Trial.
Blood. 2021 Aug 18. pii: 476603. doi: 10.1182/blood.2021012082.
PubMed Abstract available

GUO D, Zhao Y, Wang N, You N, et al
GADD45g acts as a novel tumor suppressor, and its activation suggests new combination regimens for the treatment of AML.
Blood. 2021;138:464-479.
PubMed Abstract available

ALVES DA SILVA PH, Xing S, Kotini AG, Papapetrou EP, et al
MICA/B antibody induces macrophage-mediated immunity against acute myeloid leukemia.
Blood. 2021 Aug 6. pii: 476528. doi: 10.1182/blood.2021011619.
PubMed Abstract available

YANG S, Zhu XN, Zhang HL, Yang Q, et al
ANP32B-mediated repression of p53 contributes to maintenance of normal and CML stem cells.
Blood. 2021 Aug 6. pii: 476526. doi: 10.1182/blood.2020010400.
PubMed Abstract available

SORROR ML, Storer BE, Fathi AT, Brunner A, et al
Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.
Blood. 2021;138:387-400.
PubMed Abstract available

July 2021

HALSEY C, Escherich G
A "Goldilocks" approach to CNS leukemia is needed.
Blood. 2021;138:288-289.
PubMed

SAUER T, Parikh K, Sharma S, Omer B, et al
CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity.
Blood. 2021;138:318-330.
PubMed Abstract available

TAUBE F, Georgi JA, Kramer M, Stasik S, et al
CEBPA Mutations in 4708 Patients with Acute Myeloid Leukemia - Differential Impact of bZIP and TAD Mutations on Outcome.
Blood. 2021 Jul 28. pii: 476465. doi: 10.1182/blood.2020009680.
PubMed Abstract available

KOLLMANN S, Grausenburger R, Klampfl T, Prchal-Murphy M, et al
A STAT5B-CD9 axis determines self-renewal in hematopoietic and leukemic stem cells.
Blood. 2021 Jul 28. pii: 476469. doi: 10.1182/blood.2021010980.
PubMed Abstract available

PUZZOLO MC, Radice G, Peragine N, de Propris MS, et al
Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab.
Blood. 2021 Jul 23. pii: 476452. doi: 10.1182/blood.2021011822.
PubMed

GOOPTU M, Romee R, St Martin A, Arora M, et al
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis.
Blood. 2021;138:273-282.
PubMed Abstract available

LEE JB, Khan DH, Hurren R, Xu M, et al
Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production.
Blood. 2021;138:234-245.
PubMed Abstract available

MORANDE PE, Yan XJ, Sepulveda J, Seija N, et al
AID overexpression leads to aggressive murine CLL and nonimmunoglobulin mutations that mirror human neoplasms.
Blood. 2021;138:246-258.
PubMed Abstract available

JETANI H, Navarro-Bailon A, Maucher M, Frenz S, et al
Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia (AML).
Blood. 2021 Jul 21. pii: 476427. doi: 10.1182/blood.2020009192.
PubMed Abstract available

BUTLER M, van Ingen Schenau DS, Yu J, Jenni S, et al
BTK inhibition sensitizes Acute Lymphoblastic Leukemia to asparaginase by suppressing the Amino Acid Response pathway.
Blood. 2021 Jul 19. pii: 476421. doi: 10.1182/blood.2021011787.
PubMed Abstract available

KUTSCH N
CLL-IPI: valid in the era of oral inhibitors?
Blood. 2021;138:106-107.
PubMed

PARIKH SA, Rabe KG, Kay NE, Call TG, et al
The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL.
Blood. 2021;138:149-159.
PubMed Abstract available

MULET-LAZARO R, van Herk S, Erpelinck C, Bindels E, et al
Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML.
Blood. 2021;138:160-177.
PubMed Abstract available

ZHENG W, Wei J, Zebley CC, Jones LL, et al
Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR-T-cell responses against ALL.
Blood. 2021;138:122-135.
PubMed Abstract available

KRANC KR
The essential reading list for AML: the m6A transcripts.
Blood. 2021;138:6-7.
PubMed

LINLEY AJ, Slupsky JR
Poor prognosis is ZAP70'ed into focus in CLL.
Blood. 2021;137:3586-3587.
PubMed

June 2021

MEIER-ABT F, Lu J, Cannizzaro E, Pohly MF, et al
The Protein Landscape of Chronic Lymphocytic Leukemia (CLL).
Blood. 2021 Jun 29. pii: 476272. doi: 10.1182/blood.2020009741.
PubMed Abstract available

TABE Y, Konopleva M
Break the lifeline of AML cells.
Blood. 2021;137:3465-3467.
PubMed

MORENO C
Autoimmune cytopenia and CLL ride together.
Blood. 2021;137:3464-3465.
PubMed

VITALE C, Salvetti C, Griggio V, Porrazzo M, et al
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs.
Blood. 2021;137:3507-3517.
PubMed Abstract available

MULLER MR
A new option for Richter syndrome.
Blood. 2021;137:3318-3319.
PubMed

SMOLEJ L
On the road to optimized BTK inhibition in CLL.
Blood. 2021;137:3313-3314.
PubMed

LOKE J, Cockerill PN
Unravelling the apoptotic machinery in CMML.
Blood. 2021;137:3321-3322.
PubMed

IANNELLO A, Vitale N, Coma S, Arruga F, et al
Synergistic efficacy of the dual PI3K-delta/gamma inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models.
Blood. 2021;137:3378-3389.
PubMed Abstract available

SEVIN M, Debeurme F, Laplane L, Badel S, et al
Cytokine-like protein 1-induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML.
Blood. 2021;137:3390-3402.
PubMed Abstract available

VAISITTI T, Arruga F, Vitale N, Lee TT, et al
ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models.
Blood. 2021;137:3365-3377.
PubMed Abstract available

KATERNDAHL CDS, Rogers ORS, Day RB, Cai MA, et al
Tumor suppressor function of Gata2 in Acute Promyelocytic Leukemia.
Blood. 2021 Jun 14. pii: 476182. doi: 10.1182/blood.2021011758.
PubMed Abstract available

RUBNITZ JE, Kaspers GJL
How I treat pediatric acute myeloid leukemia.
Blood. 2021 Jun 11. pii: 476140. doi: 10.1182/blood.2021011694.
PubMed Abstract available

LV K, Ren JG, Han X, Gui J, et al
Depalmitoylation Rewires FLT3-ITD Signaling and Exacerbates Leukemia Progression.
Blood. 2021 Jun 10. pii: 476131. doi: 10.1182/blood.2021011582.
PubMed Abstract available

MALOUF C, Antunes ETB, O'Dwyer M, Jakobczyk H, et al
MiR-130b and miR-128a are essential lineage-specific co-drivers of t(4;11) MLL-AF4 acute leukemia.
Blood. 2021 Jun 10. pii: 476129. doi: 10.1182/blood.2020006610.
PubMed Abstract available

CHANG Y, Min J, Jarusiewicz J, Actis M, et al
Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.
Blood. 2021 Jun 10. pii: 476126. doi: 10.1182/blood.2020006846.
PubMed Abstract available

EICHHORST B
Vaccination against COVID-19: a challenge in CLL.
Blood. 2021;137:3153-3154.
PubMed

WILLIAMS KM
Checkpoint-blocked T cells checkmate AML.
Blood. 2021;137:3155-3156.
PubMed

HERLING M, Braun T
Tracing the roots of CLPD-NK by TET2 and STAT3.
Blood. 2021;137:3156-3158.
PubMed

YUAN Y, Boyle S
All that glitters is not gold: pseudoplatelets associated with tumour lysis in high-blast-count AML.
Blood. 2021;137:3310.
PubMed

PENTER L, Zhang Y, Savell A, Huang T, et al
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.
Blood. 2021;137:3212-3217.
PubMed Abstract available

FOSTER MC, Savoldo B, Lau W, Rubinos C, et al
Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity.
Blood. 2021;137:3306-3309.
PubMed

BOLDRIN E, Gaffo E, Niedermayer A, Boer JM, et al
MicroRNA-497/195 is tumor-suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia.
Blood. 2021 Jun 7. pii: 476100. doi: 10.1182/blood.2020007591.
PubMed Abstract available

JONES RJ, DeBaun MR
Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both or neither.
Blood. 2021 Jun 3. pii: 476065. doi: 10.1182/blood.2021011488.
PubMed Abstract available

TANAKA T, Morita K, Wang F, Loghavi S, et al
Clonal Dynamics and clinical implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML).
Blood. 2021 Jun 3. pii: 476064. doi: 10.1182/blood.2020010483.
PubMed Abstract available

KORTYLEWSKI M
Revisiting TLR9 as a target for CLL therapy.
Blood. 2021;137:3006-3008.
PubMed

WERMKE M, Kraus S, Ehninger A, Bargou RC, et al
Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML.
Blood. 2021;137:3145-3148.
PubMed

SOMASUNDARAM R, Jensen CT, Tingvall-Gustafsson J, Ahsberg J, et al
EBF1 and PAX5 control pro-B cell expansion via opposing regulation of the Myc gene.
Blood. 2021;137:3037-3049.
PubMed Abstract available

DUAULT C, Kumar A, Taghi Khani A, Lee SJ, et al
Activated Natural Killer Cells Predict Poor Clinical Prognosis in High-risk B- and T- cell Acute Lymphoblastic Leukemia.
Blood. 2021 Jun 2. pii: 476053. doi: 10.1182/blood.2020009871.
PubMed Abstract available

AWADA H, Durmaz A, Gurnari C, Kishtagari A, et al
Machine Learning Integrates Genomic Signatures for Subclassification Beyond Primary and Secondary Acute Myeloid Leukemia.
Blood. 2021 Jun 1. pii: 476049. doi: 10.1182/blood.2020010603.
PubMed Abstract available

STEVENSON FK, Forconi F, Kipps TJ
Exploring the Pathways to Chronic Lymphocytic Leukemia.
Blood. 2021 Jun 1. pii: 476048. doi: 10.1182/blood.2020010029.
PubMed Abstract available

THOMS JAI, Truong P, Subramanian S, Knezevic K, et al
Disruption of a GATA2, TAL1, ERG regulatory circuit promotes erythroid transition in healthy and leukemic stem cells.
Blood. 2021 Jun 1. pii: 476046. doi: 10.1182/blood.2020009707.
PubMed Abstract available

May 2021

GHIA P, Stamatopoulos K
In CLL, epigenetics also points to the BCR.
Blood. 2021;137:2863-2865.
PubMed

MASS J, Park DC
Posttransplant T lymphoblastic lymphoma mimicking Burkitt lymphoma.
Blood. 2021;137:3002.
PubMed

COORENS THH, Collord G, Lu W, Mitchell E, et al
Clonal hematopoiesis and therapy-related myeloid neoplasms following neuroblastoma treatment.
Blood. 2021;137:2992-2997.
PubMed

WANG D, Wang J, Hu G, Wang W, et al
A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
Blood. 2021;137:2890-2901.
PubMed Abstract available

FOWLER N
Kinase inhibitors in CLL: drawing the roadmap.
Blood. 2021;137:2717-2719.
PubMed

GANSER A
What can Heraclitus tell us about AML?
Blood. 2021;137:2719-2720.
PubMed

LIU H
Basophilic myeloblasts: a clue for CML blast phase.
Blood. 2021;137:2852.
PubMed

MUSANI R, Chang H
Coexistence of BCR-ABL1 and RUNX1-RUNX1T1 in a de novo AML.
Blood. 2021;137:2853.
PubMed

DUCHMANN M, Micol JB, Duployez N, Raffoux E, et al
Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study.
Blood. 2021;137:2827-2837.
PubMed Abstract available

THIJSSEN R, Diepstraten ST, Moujalled D, Chew E, et al
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
Blood. 2021;137:2721-2735.
PubMed Abstract available

MATO AR, Ghosh N, Schuster SJ, Lamanna N, et al
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kdelta inhibitor therapy.
Blood. 2021;137:2817-2826.
PubMed Abstract available

BORELLA G, Da Ros A, Borile G, Porcu E, et al
Targeting mesenchymal stromal cells plasticity to reroute acute myeloid leukemia course.
Blood. 2021 May 19. pii: 475978. doi: 10.1182/blood.2020009845.
PubMed Abstract available

VAN DER KOUWE E, Heller G, Czibere A, Pulikkan JA, et al
Core binding factor leukemia hijacks T-cell prone PU.1 antisense promoter.
Blood. 2021 May 19. pii: 475975. doi: 10.1182/blood.2020008971.
PubMed Abstract available

BISHOP DC, Clancy LE, Simms R, Burgess J, et al
Development of CAR T-cell lymphoma in two of ten patients effectively treated with piggyBac modified CD19 CAR T-cells.
Blood. 2021 May 19. pii: 475980. doi: 10.1182/blood.2021010813.
PubMed Abstract available

ESCRIBANO SERRAT S, Calo Perez A
Pure erythroid leukemia.
Blood. 2021;137:2709.
PubMed

TAKEDA MR, Gurbuxani S
bcr3 PML-RARA: short fusion, small blasts!
Blood. 2021;137:2708.
PubMed

SURAPALLY S, Tenen DG, Pulikkan JA
Emerging therapies for inv(16) AML.
Blood. 2021;137:2579-2584.
PubMed Abstract available

KIRCHHOFF H, Karsli U, Schoenherr C, Battmer K, et al
Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL.
Blood. 2021;137:2657-2661.
PubMed Abstract available

MICKLETHWAITE KP, Gowrishankar K, Gloss BS, Li Z, et al
Investigation of product derived lymphoma following infusion of piggyBac modified CD19 chimeric antigen receptor T-cells.
Blood. 2021 May 11. pii: 475942. doi: 10.1182/blood.2021010858.
PubMed Abstract available

SILVA AP, Almeida ARM, Cachucho A, Neto JL, et al
Overexpression of wild type IL-7Ralpha promotes T-cell acute lymphoblastic leukemia/lymphoma.
Blood. 2021 May 10. pii: 475938. doi: 10.1182/blood.2019000553.
PubMed Abstract available

WIMMER J, Hurstel R
Systemic mastocytosis with an associated t(8;21)(q22;q22) acute myeloid leukemia.
Blood. 2021;137:2564.
PubMed

PADI SKR, Kraft AS
"Root"ing for successful T-ALL treatment.
Blood. 2021;137:2422-2423.
PubMed

GEOFFROY MC, Esnault C, de The H
Retinoids in hematology: a timely revival?
Blood. 2021;137:2429-2437.
PubMed Abstract available

ANAND P, Guillaumet-Adkins A, Dimitrova V, Yun H, et al
Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL.
Blood. 2021;137:2463-2480.
PubMed Abstract available

April 2021

ANDRIEU GP, Asnafi V
Integrated omics approaches to predict T-LBL relapse risk.
Blood. 2021;137:2280-2282.
PubMed

TERRE C, Raggueneau V
Double insertion in normal karyotype CML.
Blood. 2021;137:2418.
PubMed

SORROR ML, Storer BE, Fathi AT, Brunner AM, et al
Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia.
Blood. 2021 Apr 28. pii: 475848. doi: 10.1182/blood.2020008812.
PubMed Abstract available

CHATZIDIMITRIOU C, Vassilakopoulos TP
Rapidly deteriorating B-CLL at presentation: clonally related Burkitt leukemia as an atypical Richter transformation?
Blood. 2021;137:2272.
PubMed

RINGSHAUSEN I
IL-9 in CLL: sensing home and settling down!
Blood. 2021;137:2130-2131.
PubMed

SOARES F, Chen B, Lee JB, Ahmed M, et al
CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy.
Blood. 2021;137:2171-2181.
PubMed Abstract available

DA SILVA-DIZ V, Cao B, Lancho O, Chiles E, et al
A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia.
Blood. 2021 Apr 19. pii: 475782. doi: 10.1182/blood.2020008955.
PubMed Abstract available

MITTELMAN SD, Kim J, Raca G, Li G, et al
Increased prevalence of CRLF2 rearrangements in obesity-associated acute lymphoblastic leukemia.
Blood. 2021 Apr 19. pii: 475790. doi: 10.1182/blood.2021011106.
PubMed

LEW TE, Tam CS, Seymour JF
How I treat chronic lymphocytic leukemia after venetoclax.
Blood. 2021 Apr 19. pii: 475780. doi: 10.1182/blood.2020008502.
PubMed Abstract available

DI GIACOMO D, La Starza R, Gorello P, Pellanera F, et al
14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T and myeloid immature acute leukemia.
Blood. 2021 Apr 19. pii: 475778. doi: 10.1182/blood.2020010510.
PubMed Abstract available

HERISHANU Y, Avivi I, Aharon A, Shefer G, et al
Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia.
Blood. 2021 Apr 16. pii: 475742. doi: 10.1182/blood.2021011568.
PubMed Abstract available

AMES E, Silva O
Polytypic T-cell prolymphocytic leukemia.
Blood. 2021;137:2125.
PubMed

SANDBERG Y, Weerkamp F
Charcot-Leyden crystals in chronic eosinophilic leukemia.
Blood. 2021;137:1985.
PubMed

SEFTEL MD
Has MRD graduated from its adolescence in ALL?
Blood. 2021;137:1846-1847.
PubMed

KENNEDY GA, Tey SK, Buizen L, Varelias A, et al
A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis.
Blood. 2021;137:1970-1979.
PubMed Abstract available

GEMENETZI K, Psomopoulos F, Carriles AA, Gounari M, et al
Higher-order immunoglobulin repertoire restrictions in CLL: the illustrative case of stereotyped subsets 2 and 169.
Blood. 2021;137:1895-1904.
PubMed Abstract available

SHAH BD, Bishop MR, Oluwole OO, Logan AC, et al
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.
Blood. 2021 Apr 7. pii: 475697. doi: 10.1182/blood.2020009098.
PubMed Abstract available

WEI AH, Daver N
Taking aim at IDH in fitter patients with AML.
Blood. 2021;137:1706-1707.
PubMed

SCHWAB C, Roberts K, Boer JM, Gohring G, et al
SSBP2-CSF1R is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcome.
Blood. 2021;137:1835-1838.
PubMed

STEIN EM, DiNardo CD, Fathi AT, Mims AS, et al
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Blood. 2021;137:1792-1803.
PubMed Abstract available

March 2021

IACOBUCCI I, Qu C, Varotto E, Janke LJ, et al
Modeling and targeting of erythroleukemia by hematopoietic genome editing.
Blood. 2021;137:1628-1640.
PubMed Abstract available

SIMONIN M, Lhermitte L, Dourthe ME, Lengline E, et al
IKZF1 alterations predict poor prognosis in adult and pediatric T-ALL.
Blood. 2021;137:1690-1694.
PubMed

HOSOKAWA K, Mizumaki H, Yoroidaka T, Maruyama H, et al
HLA class I allele-lacking leukocytes predict rare clonal evolution to MDS/AML in patients with acquired aplastic anemia.
Blood. 2021 Mar 22. pii: 475586. doi: 10.1182/blood.2020010586.
PubMed

KOGAN SC
PML-RARalpha: changing myeloid networks.
Blood. 2021;137:1439-1440.
PubMed

ERNST MPT, Kavelaars FG, Lowenberg B, Valk PJM, et al
RUNX1 germline variants in RUNX1-mutant AML: how frequent?
Blood. 2021;137:1428-1431.
PubMed

AGATHANGELIDIS A, Chatzidimitriou A, Gemenetzi K, Giudicelli V, et al
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.
Blood. 2021;137:1365-1376.
PubMed Abstract available

NAZHA A
Should I rock the boat? When to stop TKIs in CML.
Blood. 2021;137:1136-1137.
PubMed

February 2021

DE MOERLOOSE B
CAR-T treatment of pediatric AML: a long and winding road.
Blood. 2021;137:1004-1006.
PubMed

MICHALLET AS, Letestu R, Le Garff-Tavernier M, Aanei C, et al
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
Blood. 2021;137:1019-1023.
PubMed Abstract available

WILLIER S, Rothamel P, Hastreiter M, Wilhelm J, et al
CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy.
Blood. 2021;137:1037-1049.
PubMed Abstract available

HOFF FW, van Dijk AD, Qiu Y, Ruvolo PP, et al
Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report.
Blood. 2021;137:1050-1060.
PubMed Abstract available

QAYED M, Ahn KW, Kitko CL, Johnson MH, et al
A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation.
Blood. 2021;137:983-993.
PubMed Abstract available

SERA Y, Nakata Y, Ueda T, Yamasaki N, et al
UTX maintains the functional integrity of the murine hematopoietic system by globally regulating aging-associated genes.
Blood. 2021;137:908-922.
PubMed Abstract available

LEONARD JT, Kosaka Y, Malla P, LaTocha D, et al
Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.
Blood. 2021;137:939-944.
PubMed Abstract available

GILL S
DARTs point the way forward in AML.
Blood. 2021;137:720-721.
PubMed

NG AP
Unraveling a T-ALL Tapestri.
Blood. 2021;137:726-727.
PubMed

HERGOTT CB, Pozdnyakova O
Beware the "other AML": hepatic angiomyolipoma with extensive extramedullary hematopoiesis.
Blood. 2021;137:860.
PubMed

GRANT S
Targeting cereblon in AML.
Blood. 2021;137:584-586.
PubMed

BROWN JR
AKT: a key to RT?
Blood. 2021;137:582-584.
PubMed

KOHLHAAS V, Blakemore SJ, Al-Maarri M, Nickel N, et al
Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1.
Blood. 2021;137:646-660.
PubMed Abstract available

FALINI B, Brunetti L, Martelli MP
How I diagnose and treat NPM1-mutated AML.
Blood. 2021;137:589-599.
PubMed Abstract available

January 2021

SHOUVAL R, Soiffer RJ
Primum non nocere: allo-HSCT for AML in CR1.
Blood. 2021;137:438-439.
PubMed

COHEN AUBART F, Roos-Weil D, Armand M, Marceau-Renaut A, et al
High frequency of clonal hematopoiesis in Erdheim-Chester disease.
Blood. 2021;137:485-492.
PubMed Abstract available

ZHAO Y, Aldoss I, Qu C, Crawford JC, et al
Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.
Blood. 2021;137:471-484.
PubMed Abstract available

RIO-MACHIN A, Fitzgibbon J
Germline ETV6 variants: not ALL created equally.
Blood. 2021;137:288-289.
PubMed

GAUTHIER J, Bezerra ED, Hirayama AV, Fiorenza S, et al
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
Blood. 2021;137:323-335.
PubMed Abstract available

MERTENS D, Kronke J
Triggering T-cell activity in CLL.
Blood. 2021;137:150-151.
PubMed

MASS J, Alobeid B
Composite mantle cell lymphoma and small lymphocytic lymphoma in a lymph node.
Blood. 2021;137:282.
PubMed

AL MOOSAWI M, Vercauteren S
Cerebrospinal fluid with unusual natural killer cell population.
Blood. 2021;137:281.
PubMed

IOANNOU N, Hagner PR, Stokes M, Gandhi AK, et al
Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy.
Blood. 2021;137:216-231.
PubMed Abstract available

CORRE J
Undetectable MRD can change the deal.
Blood. 2021;137:5-6.
PubMed

KEESHAN K
Superenhancing AML with Trib1.
Blood. 2021;137:8-9.
PubMed

December 2020

KAPP-SCHWOERER S, Weber D, Corbacioglu A, Gaidzik VI, et al
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.
Blood. 2020;136:3041-3050.
PubMed Abstract available

MIAO H, Kim E, Chen D, Purohit T, et al
Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations.
Blood. 2020;136:2958-2963.
PubMed

LIU Y, Panetta JC, Yang W, Karol SE, et al
Dosing-related saturation of toxicity and accelerated drug clearance with pegaspargase treatment.
Blood. 2020;136:2955-2958.
PubMed

HASELAGER MV, Kielbassa K, Ter Burg J, Bax DJC, et al
Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
Blood. 2020;136:2918-2926.
PubMed Abstract available

OBERBECK S, Schrader A, Warner K, Jungherz D, et al
Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling.
Blood. 2020;136:2786-2802.
PubMed Abstract available

SALLMAN DA, McLemore AF, Aldrich AL, Komrokji RS, et al
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.
Blood. 2020;136:2812-2823.
PubMed Abstract available

STAUBER J, Greally J, Steidl U
Preleukemic and Leukemic Evolution at the Stem Cell Level.
Blood. 2020 Dec 4. pii: 474417. doi: 10.1182/blood.2019004397.
PubMed Abstract available

November 2020

CORTES J
How to manage CML patients with comorbidities.
Blood. 2020;136:2507-2512.
PubMed Abstract available

DZAMA MM, Steiner M, Rausch J, Sasca D, et al
Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Blood. 2020;136:2442-2456.
PubMed Abstract available

WATANABE A, Miyake K, Nordlund J, Syvanen AC, et al
Association of aberrant ASNS imprinting with asparaginase sensitivity and chromosomal abnormality in childhood BCP-ALL.
Blood. 2020;136:2319-2333.
PubMed Abstract available

HANEKAMP D, Ngai LL, Janssen JJ, van de Loosdrecht AA, et al
Early assessment of clofarabine effectiveness applying measurable residual disease, including AML stem cells.
Blood. 2020 Nov 10. pii: 474126. doi: 10.1182/blood.2020007150.
PubMed

KHANAM T, Sandmann S, Seggewiss J, Ruether CM, et al
Integrative genomic analysis of pediatric T- cell lymphoblastic lymphoma reveals candidates of clinical significance.
Blood. 2020 Nov 5. pii: 474099. doi: 10.1182/blood.2020005381.
PubMed Abstract available

July 2020

BLOUIN JM, Ged C, Lalanne M, Lamrissi-Garcia I, et al
Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria.
Blood. 2020 Jul 17. pii: 461423. doi: 10.1182/blood.2020006037.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.